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Intcrleukin-10 (IL-10) is an important immuno-modulator of the B-lymphocytes. 
Single Nucleotide Polymorphism (SNP) at the IL-10 promoter positions -597, -824 
and -1087 are related lo the transcription of the gene and, hence, the serum level of 
IL-10. The SNP at the IL-10 promoters may, therefore, influence the clinical 
behaviors of lymphomas. Diffuse Large B-cell Lymphoma (DLBCL) is the most 
common type of non-Hodgkin's Lymphoma (NHL). The role of SNP in the IL-10 
promoter and the prognosis of DLBCL are controversial. Recently, the prognosis of 
DLBCL is also shown to be related to specific subtypes, namely "germinal center", 
"activated germinal center，，and "activated non-germinal center", according to the 
expressions of different antigens. The prognostic values of the SNP of the IL-10 
promoter and DLBCL subtypes in the local population are also not fully understood. 
Objective: 
The SNP of the IL-10 promoter in different subtypes of primary DLBCL were 
examined. 
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Materials and methods: 
SNP genotyping of the ILIO promoter was performed by Restriction Fragment 
Length Polymorphism on the genomic DNA extracted from formalin-fixed, 
paraffin-embedded archival sections of 144 NHL (1987-2004) and 108 primary 
DLBCL (1995-2005) patients. Genomic DNA from bufly coats of 139 healthy blood 
donors was used as control. Subtyping of DLBCL was performed with 
immunohistochemical studies using antibodies lor CD 10, Bcl-6, CD138 and MUMl. 
Clinical data were retrieved retrospectively from the case records. 
Results: 
In the local Chinese population, the most common alleles at the lL-10 promoter 
position -597, -824 and -1087 were A, T and A, respectively. The most common 
genotype was homozygosity of AA, TT and AA, respectively. A novel linkage of the 
genotype of SNP of the IL-10 promoter was noted at positions -597 and -824. The 
SNP profiles of the IL-10 promoter in the local population were those known to be 
associated with low serum IL-10 background. 
The most frequent subtype of DLBCL in the present series was "activated 
non-germinal center type", in contrast to the "germinal center type DLBCL" in 
published series, there were no significant correlation on the overall survival of local 
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DLBCL patients with all the lL-10 promoter SNPs and the different DLBCL 
subtypes. 
Ill DLBCL patients, TC at -824 position is the most frequent genotype, 
instead of TT in the controls. Unlike normal controls, the linkage between -597 and 
-824 was disrupted in some DLBCL patients. As in the normal control, ATA is the 
most frequent haplotype in DLBCL. However, in DLBCL patients, rare haplotypes 
were identified, namely ACA, ATC and GCA. These haplotypes were not found in 
normal controls. Among these three rare haplotypes, ACA was significantly more 
frequent in DLBCL than in the normal controls. 
Conclusions: 
The background SNP profiles in IL-10 promoter of the local Chinese population, 
including DLBCL patients, were those associated with low IL-10 production. Unlike 
published data on the Caucasian population, the spectrum of subtypes of local 
DLBCL was distinct. The known biomarkers for overall survival of DLBCL, 
including the SNP of IL-10 promoter and the DLBCL subtyping, appeared less useful 
clinically in the local settings. The T-allele at the IL-10 promoter position -824 and 
the rare haplotype ACA may be associated with DLBCL in the local population. 
These results suggested ethnical variations in the pathogenesis of DLBCL, 
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which may be related to a low IL-10 microenvironment. The difference in spectrum 
of subtypes and variations in prognostic fhctors of DLBCL not only further 
highlighted these ethnical differences, but also conferring significant clinical 





動區-597, -824 and-1087位點的單基因多態性與基因的表達有關，而改變白細胞 




















香港地區漢族人群白細胞介素-10啓動區-597, -824 and-1087位點的最常見 
等位基因分別是A-allde，T-allele和A-allele’最常見的基因型分別是純合子AA， 
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Chapter 1: Introduction 
1.1 Malignant Lymphoma 
Malignant lymphomas are a group of tumors derived from cells of the 
lymphorelicular system. Lymphomas are divided into two broad categories, 
Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL), depending on the 
histopathological identification of the type of neoplastic cell (Burkitt et al, 1996). HD 
is defined morphologically by the presence of scattered diagnostic neoplastic 
Modgkin's and Reed-Sternberg (RS) cells in a background of non-neoplastic 
inHammatory and accessory cells. NHL comprises the remaining forms of lymphoma 
besides HD. Globally, there were 62,329 HD cases in the year 2002, comprising 
about 17.18 % of all lymphoma cases. The mortality rate was 36.60%. The female to 
male ratio was 1:1.6 (lARC Globocan 2002 website). In Asia, HD is relatively rare 
which comprised only 9.2% in malignant lymphoma in a study of 294 adult Chinese 
lymphoma patients (Shih et al, 1991). 
1.2 Non-Hodgkin's Lymphoma 
NHL is a large heterogeneous group of disorder characterized by malignant 
proliferation of lymphoid cells (Burkitt et al, 1996). The cellular origins of most 
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types are increasingly well established with subtypes corresponding to the various 
stages of lymphocyte differentiation. Depending on the respective 
immunophenolypes, NHL can be sub-grouped into B, T and NK-cell lymphomas 
(Kato et al, 1999), 
There were 300,571 NHL cases in 2002 worldwide with a mortality rate of 
57.16%. The female to male ratio was 1:1.4. In China, there were 30,440 NHL cases 
ill 2002 with comparable mortality rate of 60.47%. The female to male ratio was 
1:1.94 (lARC Globocan 2002 website). 
While HD is typically localized to lymph nodes (Swedlow, 2003), NHL can 
arise in both nodal and extranodal sites. NHL affects not only major lymphoid 
tissue-bearing sites such as the tonsil (Levine et al, 1985), it can also involve 
locations devoid of native lymphoid tissue, such as the skin (Isaacson, 1994). 01� 
particular relevance to the local situation is that extranodal NHL has relatively higher 
incidence in Asia (Ho et al, 1984; Harris et al, 1994). 
1.3 Diffuse Large B-cell Lymphoma 
1.3.1 General Features of Diffuse Large B-cell Lymphoma 
Diffuse Large B-cell Lymphoma (DLBCL) is a diffuse proliferation of large 
neoplastic B lymphoid cells with nuclear size exceeding normal macrophage nuclei 
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or more than twice the size of a normal lymphocyte (Jaffe et al, 2001). It was 
reported to be the most common type of lymphoma as defined in the Revised 
European-American Lymphoma (REAL) classification, representing 40% of the new 
cases of lymphomas diagnosed each year (Coiffier, 2001). The median age of 
DLBCL is in the decade, but the range is broad, and it is slightly more common in 
males than females (Jaffe et al, 2001). This trend of DLBCL remains the same under 
the new classification of the World Health Organization. 
DLBCL may present in nodal or extra-nodal sites. Up to 40% are confined to 
extra-nodal sites and the most common extra-nodal site is the gastrointestinal tract 
(stomach or ileo-cecal region) (Harris et al, 1994). However, DLBCL can virtually 
present in any extra-nodal location including the skin, the central nervous system 
(CNS), the bone, the testis, the soft tissue, the salivary glands, the female genital tract, 
the lungs, the kidneys, the liver, the Waldeyer's ring and the spleen (Jaffe et al, 
2001). 
The causes of DLBCL remain unknown (Coiffier, 2001). They usually arise 
ck mm) (primary DLBCL) but can be resulted from progression or transformation 
(secondary DLBCL) of a less aggressive lymphoma such as chronic lymphocytic 
leukemia/ small lymphocytic lymphoma (CLL/SLL), follicular lymphoma, marginal 
zone B-cell lymphoma or nodular lymphocyte predominant Hodgkin's disease. (Jaffe 
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et al, 2001). 
Although most patients respond initially to chemotherapy, only 35 to 40% of 
patients achieve durable remission (Rosenwald et al, 2003) and more than half 
succumb to their disease (de Leval et al, 2003). 
DLBCL is much more heterogeneous, in terms of clinical behavior and 
histomorphologic features, than other groups of lymphomas (Brittinger et al, 1984). 
DLBCL occurs over a broad range of ages and manifests al nodal or extraiiodal sites 
(Harris et al, 1994). DLBCL consists of several morphologic variants including 
anaplastic, centroblastic, immiinoblastic, and T-cell/histiocyte-rich subtype (Reed et 
al, 1977). However, no distinct prognostic significance has been correlated with any 
of these histomorphologic variants in recent lymphoma classification systems (Harris 
et al, 1994). 
1.3.2 Morphologic variants of Diffuse Large B-ccll Lymphoma 
DLBCL are composed of large transformed lymphoid cells. Cytologically, 
DLBCL are very diverse and can be divided into several morphologic variants, 
namely, centroblastic, immunoblastic and anaplastic (Harris et al, 1994). However, 
distinction among these variants has generally met with both poor inlra-observer and 
inter-observer reproducibility (Harris et al, 1994). Moreover, prognosis of patients 
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cannot be predicted by this classification. Immunopehiiotypic and genolypic 
parameters are suggested to provide superior prognostic information of DLBCL 
patients (Chang et al, 2004; Alizadeh et al, 1999). 
1.3.2.1 Centroblastic vairant 
This is the most common morphologic variant and is composed of medium 
sized to large lymphoid cells with oval to round, vesicular nuclei containing fine 
chromatin and 2 to 4 membrane bound nucleoli. The cytoplasm is generally scanty 
and amphophilic to basophilic. This variant may have a monomorphic or 
polymorphic appearance (Engelhard et al, 1997). In some cases the cells may be 
multilobated. 
1.3.2.2 Immuiioblastic variant 
More than 90% of cells in this variant are with a single, centrally-located 
nucleolus and an appreciable amount of basophilic cytoplasm. Immunoblasts with 
plasmacytoid differentialtion may also be present. Less than 10% of centroblasts are 
present in the population. (Jaffe et al, 2001) 
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1.3.2.3 Anaplastic variant 
This variant is characterized by very large round, oval or polygonal cells with 
bizarre pleomorphic nuclei which may resemble Reed-Sternberg cells. The cells may 
grow in a cohesive pattern, mimicking carcinoma, or may show a sinusoidal pattern 
of growth (Haralambieva et al, 2000). 
1.3.3 Iinmunophciiotype of Diffuse Large B-cell Lymphoma 
1.3.3.1 Lineage-associated antigens 
1.3.3.1.1 B-cclI lineage antigens 
DLBCL usually expresses CD45 (leucocyte common antigen) and pan-B-cell 
antigens, such as CD 19，CD20 and CD79a, but may lack one or more of these 
markers (Jaffe et al, 2001). CD20 is a transmembrane protein that functions as a Ca^ "*" 
permeable cation channel. CD20 is expressed on B-cells from the stage of the 
precursor B-cell until the preplasma cell stage of differentiation (Chang et al, 1996). 
CD79a, which is part of a heterodimer associated in the B-cell membrane with 
immunoglobulin, is expressed on precursor B-cells and is retained throughout B-cell 
differentiation until a later stage than CD20. In most plasma cells, CD79a is positive 
(Mason et al, 1995). Both CD20 and CD79a are highly specific markers of B-cell 
lineage. Rare cases of peripheral T-cell lymphomas were positive for CD20 
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(Qiiintanilla-Martinez et al, 1994). 
Intrinsic surface immunoglobulin (sig) is a specific marker for B-cells that is 
expressed uniquely by this lymphocyte population and serves as the 
antigen-recognition molecule for B-cells (Knowles, 2001). The majority of B-cell 
lymphomas, including DLBCL, express monotypic sIg, usually of the IgM subtype 
(Lamarre et al, 1989). Since the Ig idiotype is a potential target of cytotoxic cells 
(Kwak et al, 1992), defective expression of the sIg might be a route for immune 
escape. 
1.3.3.1.2 T-cell lineage antigens 
CD5, found primarily in T-cells, is also expressed by a small subset of normal 
B-cells, the B-1 cells (Kipps, 1989). CDS is a characteristic antigen ofCLL/SLL and 
mantle cell lymphoma (MCL). Only a small proportion of about 10% of the DLBCL 
expresses CDS (Burns et al, 1983). CD5 positive DLBCL occurs de novo rather than 
as a manifestation of transformation of CLL/SLL (Yamaguchi et al, 2002). CD5 
positive DLBCLs are negative for cyclin D1 expression, distinguishing them from 
blastoid MCL (Jaffe et al, 2001). The de novo CD5-positive DLBCL is a highly 
aggressive subtype of DLBCL. CD5—positive DLBCL has significantly poorer 
prognosis than those of CD5 negative cases (Yamaguchi et al, 2002). 
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1.3.3.2 Antigen involved in regulation of cell proliferation and apoptosis 
1.3.3.2.1 Proliferation markers 
Several studies have examined the impact of cell proliferation in DLBCL. The 
monoclonal aiili-Ki67 antibody is widely used as a proliferation marker (Gerdes et 
all, 1984). The proportion of cells expressing Ki67 defines the fraction of actively 
cycling cells. In DLBCL, the cell cycle fraction is variable, usually ranging from 30 
to 100%, but is typically high with median values around 65% (Hall ct al, 1988). 
Moreover, it lias been reported that high expression of Ki67 in DLBCL patients was 
associated with shorter overall survival and, hence, with poorer prognoses (Sanchez 
et al, 1998). 
1.3.3.2.2 Cell cycle regulators 
Cell cycle progression is regulated by a complex molecular network involving 
cyclins, cyclin-dependent kinases (CDK) and CDK inhibitors. The two major 
regulatory pathways are the p53 pathway, which regulates apoptosis and cell cycle 
arrest in Gl , and the Rb pathway, which regulates the transition from G1 to S. 
Genetic alterations and/or dysregulation of these factors are frequently detected in 
DLBCL. 
The p53 gene is one of the most frequently mutated genes in human cancer. The 
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p53 protein, referred to as ‘the guardian of the genome', monitors DNA integrity. The 
p53 protein arrests cells at G1 or programs the cells to cell death when DNA 
replication is defective or when DNA is damaged (Levine et al, 1991). Mutations of 
the p53 gene, leading to a functionally defective protein, have been detected in about 
20% of DLBCL (Ichikawa et al, 1997). Mutations of the p53 gene in DLBCL are 
associated with clinical drug resistance (Wilson et al, 1997) and poor outcome 
(Lei'oy et al, 2002). The p53 protein is not detected by immunohistochemistry in 
normal cells because of its rapid degradation. Either p53 gene mutation affecting p53 
lurnover, or accumulation of wild-type p53 can result in detectable protein. In 
DLBCL, p53 is detectable by immunohistochemistry in 30 to 40% of the cases. In 
some of these cases, immuiioreactivity of p53 in DLBCL cells is seen in the absence 
of mutation of the p53 gene (Gascoyne, 1997). 
The retinoblastoma (Rb) protein negatively regulates the Gl/S transition of the 
cell cycle (Sanchez et al, 1998). In DLBCL, loss of Rb expression is an adverse 
prognostic factor. High Rb expression (>80% positive cells) is associated with 
extended survival times (Sanchez et al, 1998). 
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1.3.3.2.3 Protein controlling apoptosis 
The Bcl-2 protein is located in the mitochondrial inner membrane functions and 
acts as an anti-apoptotic protein, protecting the cells from programmed cell death 
(Hockenbery et al, 1990). In DLBCL, Bcl-2 protein expression is found in 30 to 60% 
of the cases. Bcl-2 imniunoreactivity is more frequently detected in nodal form than 
in exlranodal DLBCL (Piris et al, 1994). Expression of Bcl-2 protein is related to 
poor prognosis in DLBCL patients (Biasoli et al, 2005). With a combination of poor 
prognostic factors, DLBCL patients of high International Prognostic Indicator, 
having Bcl-2 protein expression and the lack of germinal center phenotype are 100% 
fatal in less than 3 years (Barrans et al, 2002). 
1.3.4 Subtypes of Diffuse Large B-cell Lymphoma 
It has been well documented that DLBCL expressing germinal center 
phenotype-related protein, Bcl-6, is associated with better prognosis (Barrans et al, 
2002; Lossos et al, 2000). Recent studies substantiated this finding and refined the 
classification of DLBCL, with the employment of new technologies including DNA 
microarray technique (Alizadeh et al, 2000) and immunohistochemical technique 
with a panel of antibodies (Chang et al, 2004). It is important to develop a technique 
lhat can classify the subtype of DLBCL accurately for the prognostic estimation. 
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1.3.4.1 Classification method of DLBCL subtypes 
1.3.4.1.1 DNA microarray 
Technical and analytical advances make it possible to investigate the expression 
of thousands of genes at the same time using complementary DNA microarray. To 
apply this technique to research in normal and malignant lymphocytes, a 
'Lymphochip', which contains genes that are preferentially expressed in lymphoid 
cells and genes with known or suspected role in the processes important in 
immunology or cancer, was developed (Alizadeh et al, 2000). This Lymphochip 
contains 12,069 cDNA clones chosen from a germinal center B-cell library, and 
2,338 cDNA clones from libraries derived from DLBCL, follicular lymphoma, 
mantle cell lymphoma and chronic lymphocytic leukemia libraries. In addition, 
clones representing a variety of genes that are induced or repressed during B- and 
T-lymphocyte activation by mitogens or cytokines and a curated set of 3,186 genes of 
importance to lymphocyte and/or cancer biology were also added to this Lymphochip 
(Alizadeh et al, 1999). 
Clustering analyses of the patterns of gene expressions in DLBCL identified 
two large branches of DLBCL, namely，the germinal center B-cell DLBCL and the 
activated B-cell DLBCL. The germinal center B-cell DLBCL expresses, to a varying 
degree, all of the genes that define the germinal center B-cell signature. In contrast, 
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the activated B-cell DLBCL expresses these genes at low or even undetectable levels, 
Fig. 1.1a. A distinct set of genes, corresponding to activation of the B-cells, are 
differentially expressed in this second large subgroup of DLBCL, Fig. 1.1c. The 
germinal center B-cell DLBCL and activated B-cell DLBCL could not be 
distinguished morphologically. More importantly, there is association of germinal 
center B-cell DLBCL with belter prognosis. Hence, DNA microarry analysis 
provides a way to molecular classify DLBCL by distinguishing germinal center 
B-cell DLBCL and activated B-cell DLBCL with their respective specific gene 
expression patterns. Such classification is useful and can allow prognostic 
information to be estimated. 
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Figure 1.1 Discovery of DLBCL subtypes by gene expression profiling. The samples 
used in this clustering analysis are shown as bottom, a，Hierarchical clustering of 
DLBCL cases (blue and orange) and germinal center B-cells (black) based on the 
genes of the germinal center B-cell gene expression signature. Two DLBCL 
subgroups, germinal center B-cells DLBCL (orange) and activated B-cell DLBCL 
(blue) were defined by this process, b, Discovery of genes that are selectively 
expressed in germinal center B-cell DLBCL and activated B-cell DLBCL. All genes 
from Lymphochip, with the exception of the genes in the proliferation, T-cell and 
lymph-node gene expression signatures, were ordered by hierarchical clustering 
while maintaining the order of samples determined in Fig.la. Genes selectively 
expressed in germinal center B-cell DLBCL (orange) and activated B-cell DLBCL 
(blue) are indicated, c, Hierarchical clustering of the genes selectively expressed in 
germinal center B-cell DLBCL and activated B-cell DLBCL, which was determined 
from Fig. lb. (Alizadeh et al, 2000) 
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1.3.4.1.2 Immunohistochemistiy pattern 
Although thousands of genes of DLBCL can be studied in parallel by DNA 
microarray, the gene expression profiling studies are currently not practical in the 
clinical laboratory setting because of the exceedingly high cost associated with the 
cDNA microarray technology and the need for fresh or frozen tissue. 
For routine clinical practice, immunohistochemical markers may be used on 
formalin-fixed paraffin-embedded tissue to classify DLBCL (Chang et al, 2004). 
DLBCL subtypes can be classified by staining CDIO and Bcl-6, which are known 
markers for the germinal center B-cell. These two markers arc also shown to be 
highly expressed in germinal center B-cell DLBCL in DNA microarray experiments. 
MIJM1/1RF4 and CD 138, which are expressed by the activated B-cells that have the 
capacities of differentiation toward plasma cells, can be used in parallel for the 
identifying of activated B-cells component. With these four antigens, 4 subtypes of 
DLBCL can be classified, namely, germinal center DLBCL, activated germinal 
center DLBCL, activated non-germinal center DLBCL and an unclassified category 
(Chang et al, 2004 and Table 1.1). Fig. 1.2 shows a schematic diagram summarizing 
the expression of these 4 antigens with respect to various stages of B-cell 
differentiation. 
14 
CDIO and/or Bcl-6 CD138 and/or MUMl 
Germinal Center -





Table 1.1 Siiblyping of DLBCL by immunohistocliemical staining of antibodies 
against CDIO, Bcl-6, CD 138 and MUMl 
a posilivily is defined as any staining intensity with more than 20% of lymphoma 
cells showing the specific staining patterns of the respective antibodies. 
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1.3.4.1.2.1 CDIO 
CD 10 is also known as the Common Acute Lymphoblastic Leukemia Antigen 
(CALLA). It is a membrane metalloproteinase that is detected in early lymphoid 
progenitors as well as in a variety of stromal and epithelial cells (LeBien et al, 1989). 
CDIO is expressed by the majority of follicular lymphomas, while other small B-cell 
lymphomas do not express this antigen. In DLBCL, CDIO expression on paraffin 
sections is detected in 20-40% of the cases (de Leval et al, 2003). 
1.3.4.1.2.2 Bcl-6 
Bcl-6 is a nuclear phosphoprotein belonging to the BTB/POZ (bric-a-brac, 
tramtrack, broad complex/Pox virus zinc finger) zinc finger family of transcription 
factors (Zollman et al, 1994). It is an effective transcriptional repressor of wide 
variety of genes (Chang et al, 1996). Along the B-cell lineage, Bcl-6 is specifically 
expressed only in mature B-cells within the germinal center (Cattorelti et al, 1995). 
Bcl-6 is essential for the formation of the germinal center B-cells (Yeh et al, 1997). 
The mRNA of Bcl-6 and its protein are significantly higher in germinal center B-cell 
than resting B-cell. However, the exact function of Bcl-6 in germinal center 
formation of B-cell remains unclear (Allman et al, 1996). Bcl-6 is not found in 
pre-B-cells or in the differentiated progenies, for example plasma cells. These 
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observations suggested that Bcl-6 is down regulated in post germinal center B-cells. 
In DLBCL, about 35 to 40% of cases expressing Bcl-6 (Pasqualucci et al, 2003). 
1.3.4.1.2.3 CD138 
CD 138, also known as Syndecan-1, is an important transmembrane heparin 
sulphate proteoglycan which is expressed by normal bone marrow-derived B-cell 
precursors. CD 138 is absent in the naive and germinal center B-cells. CD 138 is then 
re-expressed as B cells exit the germinal center and mature in to plasma cells 
(Sanderson et al, 1989). Little is known about the normal function of CD138 and its 
role in lymphoid malignancies. 
1.3.4.1.2.4 MUM1/IRF4 
MUM1/IRF4 protein is the gene product involved in the myeloma-associated 
chromosomal translocation t(6;14)(p25;q32). MUMl is a phenotypic marker for 
B-cell differentiation. In normal B-cells, MUMl expression is thought to denote the 
final step of intra-germinal centre B-cell differentiation and subsequent steps of 
maturation towards plasma cells. In normal lymphoid tissue, MUMl expression is 
detected by immunohistochemistry (Falini et al, 2000) with cytoplasmic/nucleus 
pattern. In DLBCL, MUMl is detected in 50 to 75% of the cases. Its expression in 
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DLBCLs may reflect derivation from B-cells at a late germinal center or 
post-germinal center stage of differentiation, up to the terminal stage of the plasma 
cell (de Leval et al, 2003). 
Germinal centre B cells 丨！ 
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Figure 1.2 This scheme depicts expression of stage-specific differentiation antigens 
in relation to normal B-cell differentiation, i.e. pre-germinal center (GC), GC and 
post-GC stages, (de Leval et al, 2003) 
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1.3.4.2 Prognosis of DLBCL subtypes 
Clinical data are being used to provide prognostic information for DLBCL. An 
International Prognostic Indicator (IPI) is defined taking into account patient's age, 
performance status, and the extent and location of the disease. The IPI correlates with 
the prognosis of subtypes in DLBCL. This indicator provides an effective index for 
therapeutic planning and for research purposes in the study of clinical outcomes. 
Besides clinical data, laboratory investigations were explored to provide 
reproducible and objective markers for prognosis of DLBCL. In both studies of 
Alizadeh et al. and Chang et al., using DNA microarray and immiinohistochemistry 
method, respectively, classification of DLBCL into subtypes have prognostic 
significance. Both studies showed that patients in the activated B-cell DLBCL have 
distinctly worse overall survival than patients in the germinal center B-cell subtype 
(Alizadeh et al, 2000; Chang et al, 2004). The Kaplan-Meier plot of survival data of 
patients of both studies are shown in Fig. 1.3 and 1.4, respectively. 
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Figure 1.3 Clinically distinct DLBCL subtypes defined by gene expression profiling, 
a, Kaplan-Meier plot of overall survival of DLBCL patients grouped on the basis of 
gene expression profiling, b, Kaplan-Meier plot of overall survival of DLBCL 
patients grouped according to the International Prognostic Index (IPI). Low clinical 
risk patient (IPI score 0-2) and high clinical risk patients (IPI score 3-5) are plotted 
separately, c, Kaplan-Meier plot of overall survival of low clinical risk DLBCL 
patients grouped on the basis of their gene expression profiles. (Alizadeh et al, 2000) 
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Figure 1.4 A: Patients with expression pattern of germinal center B-cell DLBCL 
have a better overall survival (OS) than those with the other two patterns. B: Patients 
with low IPl scores have a better OS than those with high IPI scores. C: Among 
patients with low IPl score, the patients with expression of pattern of activate 
germinal center and activated non-germinal center DLBCL have a worse OS than 
those with expression pattern of germinal center DLBCL. D: Among patients with 
high IPI score, the same trend is observed. (Chang et al, 2004) 
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1.4 Interleukin 10 
Interleukin 10 (IL-10) was first described as cytokine synthesis inhibitory factor 
(CSIF) (Fiorentino et al, 1989) and is activity produced by mouse Th2 cells that 
inhibit the activation and production of cytokine by Thl cells. The IL-10 protein is 
18kDa in molecular weight and consists of 178 amino acids. Early studies suggested 
that IL-10 is dimeric (Fiorentino et al, 1989). Biochemical (Syto et al, 1998) and 
X-ray crystallography (Zdanov et al, 1995) analyses of IL-10 demonstrated that the 
protein is an acid-sensitive, non-covalent homodimer of two interpenetrating 
polypeptide chains, Fig. 1.5. 
A B 
Figure 1.5 A, Monomer of Interleukin 10. B, Non-covalent Homodimer of 
Interleukin 10. (Research Collaboratory for Structural Bioinformatics, Protein Data 
Base website) 
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1.4.1 The IL-10 gene 
The IL-10 gene consists of five exons and is located in chromosome 1 (Spits 
and de waal Malefyt, 1992). Upon activation, IL-10 gene expresses a 2kb mRNA. 
IL-10 is expressed by varieties of cells, such as T-cells, monocytes and macrophages 
(Moore et al, 2001). IL-10 transcription can be regulated by the transcription factors, 
Spl and Sp3. The latter two genes are expressed constitutively by many different cell 
types (Tone et al, 2000). The stability of IL-10 mRNA can also be controlled at the 
post-transcriptional level by alteration of the post-transcriptional RNA degradation 
mechanism (Powell et al, 2000), this further facilitates rapid control of IL-10 
expression. 
1.4.2 IL-10 promoter 
The IL-10 promoter is highly polymorphic. Two informative microsatellites, 
IL-10.G and IL-IO.R, are located 1.2kb and 4kb upstream of the transcription start 
site, respectively (Eskdale et al, 1997). A correlation of microsatellite IL-10.R and 
low IL-10 secretion of lipopolysacharide (LPS)-induced peripheral blood 
mononuclear cells in vitro was reported (Eskdale et al, 1998). 
There are three frequent point mutations -1087(G/A), -824(C/T), and 
-597(C/A) (Turner et al 1997; Hurme et al, 1998) in the IL-10 promoter. The -1087 
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G-allele was associated with higher IL-10 production (Turner et al, 1997). The 
I 
transcription lactors of the Ets family are key regulators of the genes involved in the 
immune response and cellular proliferation. In the IL-10 promoter, the -1087 A-allele 
matches the GGAA Ets binding site core motif, but the -1087 G-allele does not. The 
specific transcription foctor for the IL-10 promoter was further characterized as PU.l. 
PU.l is an Ets family member expressed in all hematopoetic cell lineages except the 
peripheral T-cells. It was further demonstrated that the -1087 A-allele, but not the 
G-allele, confers optimal affinity for PU.l. The binding of the latter inhibits IL-10 
expression (Reuss et al, 2002). Therefore, the -1087 G-allele is associated with high 
IL-10 secretion. 
1.5 IL-10 rcceptor 
IL-10 receptor is composed of two different chains, the a (Ho et al, 1993) and p 
(CRFB4) (Kotenko et al, 1997) chains. The (3 chains belong to the interferon receptor 
(IFNR) family (Moore et al, 2001). 
IL-lORa, mapped on chromosome llq23.3, is the ligand-binding subunit that 
binds IL-10 with high affinity (Kj ~35-200pM) (Liu et al, 1994; Tan et al, 1993). 
Immunoprecipilation study indicated a molecular size of 90-120kDa for IL-lORa 
(Liu et al, 1994). Epitope and peptide mapping data generally supported these 
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observations (Tan et al, 1995). 
IL-10R(3 was originally described as orphan IFNR family member 
CRFB4/CRF2-4 located in the IFNR gene complex on chromosome 21 (Lutfalla et al, 
1993; Gibbs et al, 1997). It is essential for IL-IO mediated effects and 
CRFB4-deficient mice display the same phenotype as IL-IO deficient mice (Spencer 
et al, 1998). Its principal function appears to be recruitment of a Jak kinase (Tyk2) 
into the signaling complex (Kotenko et al, 1997). 
1.6 Cellular Signaling Pathways Regulated by IL-IO 
1.6.1 Jak/Stat Pathway 
The IL-IO/IL-IOR interaction engages the Jak family tyrosine kinases Jakl, 
being associated with IL-lORa, and Tyk2, being associated with IL-lORp (Finbloom 
et al, 1995). lL-10 induces tyrosine phosphorylation and activation the latent 
transcription factors Stat3, Statl and, in non-macrophage cells, Stat5 (Finbloom et al, 
1995). 
The relationship between the biology of IL-IO and IL-IO signaling molecules 
and pathways has been identified in both in vitro and in knock out mice studies. 
Macrophages from Jakl -/- mice do not respond to IL-IO (Rodig et al, 1998), which 
indicates that Jakl plays an obligatory role in IL-IO signaling. Stat3 is also 
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implicated strongly as a key mediator of IL-10 responses. Stat3 is recruited directly 
to the IL-IO/IL-IOR complex via either of the two tyrosine residues in the IL-lORa 
cytoplasmic domain. These tyrosine residues are phosphorylated in response to IL-10 
(Weber-Nordt et al, 1996) and these tyrosine residues are required for IL-10 signaling 
(Weber-Nordt et al, 1999). Overexpression of a dominant negative Stat3 mutant or an 
indiicibly active form of Stat3 demonstrated that Stat3 activation was both necessary 
and sufficient to mediate inhibition of macrophage proliferation by IL-10 (O'Farrell 
et al, 1998). 
In contrast to Stat3, the roles of Stall and Stat5 in the IL-10 biology and signal 
transduction remain unclear. Statl and Stat5 do not appear to interact directly with 
the IL-IO/IL-IOR complex (Weber-Nordt et al, 1996). Overexpression of dominant 
negative Statl or StatS did not block IL-lO's effects on a macrophage cell line 
(O'Farrell et al, 1998). Moreover, macrophages from Statl -/- mice remain 
responsive to IL-10 (Meraz et al, 1996). 
1.6.2 Inhibition of NFKB pathway 
IL-10 controls inflammatory processes by suppressing the expression of 
pro-inflammatory cytokines, chemokiiies, adhesion molecules, as well as 
antigen-presenting and co-stimulatory molecules in monocytes/macrophages, 
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neutrophils and T-cells. (Moore et al, 2001). As all of these inflammatory proteins are 
transcriptionally controlled by NFKB, it was suggested that IL-10 may exert a 
significant part of its anti-inilammatory properties by inhibiting this transcription 
lactor. 
IL-10 inhibits NFkB activity in two different ways: 1) IL-10 blocks NFkB 
nuclear translocation by inhibiting IKK activity (Yin et al, 1998); and 2) IL-10 
blocks DNA-binding of N F K B that is already present IN the nucleus (Schottelius et al, 
1999). Since the inhibition of nuclear N F K B could not be explained by an increase of 
nuclear levels OF its inhibitor IKB (Schottelius et al, 1999), the mechanisms 
underlying this observation needs to be further investigated. 
1.7 Function of IL-10 
1.7.1 Effects of IL-10 on immune cells in vitro 
Antigen-presenting cells and lymphocytes are the primary targets of IL-10. 
Direct effects on these populations explain the major immunological impact of this 
cytokine, including the regulation of the Thl/Th2 balance (Asadullah et al, 2003). 
IL-10 promotes the development of a type 2 cytokine pattern, which inhibits the 
IFN-y production of T lymphocytes via the suppression of IL-12 synthesis in 
accessory cells. IL-10 co-stimulates the proliferation and differentiation of B-cells, 
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which is important in the mounting of adequate defense against intestinal parasites, 
neutralization of bacterial toxins, and in local mucosal defenses (Romagnani, 1995). 
Moreover, IL-10 suppresses pro-inflammatory cytokine production and the 
antigen-presenting capacity of monocytes/macrophages and dendritic cells (De Waal 
Malefyt et al, 1991; Fiorentiiio et al, 1991). Therefore, IL-10 acts as a substantial 
suppressor of the cellular immunity (Spits and De Waal Malefyt, 1992). 
1.7.2 Effects of IL-10 on B-tells 
The effects of IL-10 on the survival, proliferation and differentiation of human 
B-cells have been extensively studied. IL-10 enhances survival of normal human 
B-cells, which correlates with the increased expression of the anti-apoptotic protein, 
Bcl-2 (Levy and Brouet, 1994). IL-10, together with soluble anti-lgM, can upregulate 
telomerase activity in activated B-cells (Hu et al, 1999). IL-10 is a potent cofactor for 
proliferation of human B-cell precursors and mature B-cells activated by anti-lgM or 
CD40 cross-linking (Rousset et al,1992; Saeland et al, 1993). This IL-10 induced 
proliferation of activated B-cells was further enhanced by both IL-2 and IL-4. The 
synergistic effect with IL-2, in particular, correlates with IL-10 enhanced expression 
of high-affinity IL-2 receptor on these B-cells. (Fluckiger et al, 1993). 
IL-10 also affects B-cell in differentiation. In long-term culture of B-cells 
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stimulated by either anti-CD40, activated T-cells or follicular dendritic cells, addition 
of IL-10 induces difl'erentiation of B-cells into plasma cells (Rousset et al, 1995). 
IL-10 acts synergistically with CD27/CD70 signals to induce plasma cell 
differentiation from CD27+ memory B-cells (Agematsii et al, 1998). IL-10 is a very 
important cytokine for B-cell function. 
1.8 IL-10 and IL-10 receptor in malignant diseases 
1.8.1 Melanoma 
It has been demonstrated that significant IL-10 mRNA expression is found in 
melanoma and melanoma metastases but not in healthy skin. This suggests that 
melanoma cells themselves are contributing at least in part to the IL-10 
overexpression (Kruger-Kraskagakes et al, 1994). The overexpression of IL-10 may 
be of particular pathogenetic importance. IL-10 functions as autocrine growth factor 
for malignant melanoma and reduces the expression of HLA class I and II on 
melanoma cell (Yue et al, 1997). IL-10 stimulates the growth of melanoma cell and, 
in addition, masking the tumor cells from the host immune system. 
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1.8.2 Carcinoma 
There are reports on the overexpression of IL-10 in basal cell and squamous cell 
carcinoma of the skin (Kim et al, 1995). Cytotoxic T-cell lines recognizing these 
tumors proliferated in the presence of the tumor cells only when IL-10 was 
neutralized by monoclonal antibodies. On the other hand, the intralesional injection 
of IFN-a resulted in tumor regression that was associated with the down-regulation 
of IL-10 niRNA expression. IL-10 seems to be an important mediator in evading the 
T cell-mediated immune response in these cutaneous malignancies (Kim et al, 1995). 
Little is known about IL-10 in other types of epithelial malignancies. It has 
been demonstrated that -1087 A A genotype is associated with the renal cell 
carcinoma, however the biological and clinical significances for this observation 
remain unknown (Havranek et al. 2005). 
1.8.3 Lymphoma 
Tumor cells from B, T, and NK cell lymphoma are able to produce biologically 
active IL-10 (Kitabayashi et al, 1995; Masood et al, 1995; Sjoberg et al, 1996; Beatty 
et al, 1997; Boiilland et al, 1998; Jones et al, 1999). As early as 1993, elevated IL-10 
serum levels were found in patients with active NHL. Elevated IL-10 is detected in 
serum from about 50% of these NHL patients. IL-10 was detectable with a similar 
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frequency in all subtypes of NHL and in all clinical stages, as well as in both 
EBV-seropositive and EBV-seronegative patients (Blay et al, 1993). Moreover, this 
elevated serum IL-IO levels are associated with poor prognosis of the NHL patients 
(Blay et al, 1993). These observations suggested that the elevation of serum IL-IO 
levels in NHL is associated with the presence of an active disease. In the following 
years these observations were extended to HD and more lymphoma types. 
Lymphoma patients have significantly higher serum levels of IL-IO than healthy 
volunteers (Cortes et al, 1995; Cortes and Kurzrock, 1997; Sarris et al, 1999; Bohlen 
el al, 2000; Vassilakopoiilos et al, 2001; Fayad et al, 2001). 
Ill different lymphomas, increase lL-10 production is related to negative 
prognosis of the patients. (Blay et al, 1993; Stasi et al, 1994; Cortes et al, 1995). 
Elevated lL-10 serum levels have been described as a negative prognostic factor for 
responsiveness toward treatment, disease-free duration and the overall survival with 
extranodal lesions. After radially resection of the primary lesion, the serum levels of 
IL-IO return to normal in some of these lymphoma patients. Persistently elevated 
IL-IO serum levels after surgery predicts tumor recurrence (Galizia et al, 2002; 
Uwatoko et al, 2002). Moreover, a further significant increase in IL-IO serum levels 
has been observed in iion-respoiiders after chemotherapy (Wojciechowska-Lacka et 
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1.9 Single Nucleotide Polymorphism (SNP) 
One important observation in the human genome project is that the extent of 
genetic variation is much larger than previously estimated (Lander et al, 2001; Venter 
et al, 2001). The most common sequence variation in the human genome is the stable 
substitution of a single base, called Single Nucleotide Polymorphism (SNP). By 
definition, a SNP has a minor allele frequency of greater than 1% in at least one 
population (Risch, 2000). Most SNPs are silent and do not alter the function of a 
gene. It is different from the term 'mutation' used for rare variants, such as those 
found in classical monogenic disorders. 
The total number of SNPs in the human genome is estimated to be more than 10 
million (Botstein and Risch, 2003). The number of SNPs with minor allele frequency 
of over 10% is estimated to be as many as five million (Kruglyak and Nickerson, 
2001). SNPs are distributed throughout the human genome, at an estimated overall 
frequency of at least one in every 1000 base pair (bp) (Carlson et al, 2003). There are, 
however, marked regional differences of the density of SNP in the human genome. 
SNP arises because of point mutations that are selectively maintained in populations. 
The SNP frequencies are determined by: (1) the amount of time elapsed since the 
variation occurred; (2) evolutionary pressure on biologically significant variants and 
those linked to the functional variants; (3) random genetic drift; and (4) bottleneck 
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events (Erichsen and Chanock, 2004). 
Single nucleotide polymorphisms in the same chromosomal region are not 
inherited randomly. They do so as combinations of alleles, which form haplotype 
blocks. It appears that the genome is organized into distinct blocks of linkage 
disequilibrium (LD), intercepted by regions in which LD breaks down rapidly 
(Bonnen et al, 2002; Sabeti et al, 2002). Thus the complexity oT analyzing SNPs in a 
gene or locus can be reduced by the analysis of markers inherited on a haplotype. It 
is notable thai both the frequency of SNPs and the extent of LD may vary 
significantly between populations. In addition, there are many population-specific 
private variants (Carlson et al, 2003). 
1.9.1 SNPs in cancer research 
Genetic association studies with SNPs targeting cancer can be divided into two 
broad categories: investigation of susceptibility or the association with outcomes. 
The latter seeks to determine prognostic information for survival, complications or 
response to pharmacological intervention. 
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1.9.1.1 Susceptibility to cancer and SNPs 
The aetiology of a specific cancer is probably associated with a set of genetic 
variants, many of which could adversely interact with environmental factors. It is 
notable that some SNPs or haplotypes can be protective. Other SNPs may confer 
increased susceptibility. For example, certain SNPs in the myeloperoxidase promoter 
will lead to low risk for developing lung cancer (London et al, 1997). Some SNPs in 
N-acetyltraiisferase 1 gene will lead to higher risk to develop bladder cancer (Hein, 
2002). 
1.9.1.2 Outcome and SNPs 
Pharmacogenomics is the study of the inherited basis of inter-individual 
differences in drug response. It has been estimated that inherited differences account 
for inter-individual variations in drug responses (Kalow et al, 1998). 
Investigations for candidate genes have focused on those genes related to drug 
metabolism. This includes studies of genes involved in the uptake, activation, 
degradation and excretion of drugs. The aims are to identify SNPs that are associated 
with life-threatening adverse reactions. Armed with knowledge of these validated 
SNPs and haplotype markers that are associated with adverse drug reactions, 
clinicians could perform screening tests to identify patients at risk. If indicated, 
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tailored therapy can be designed for patients with specific susceptibility to adverse 
drug reactions. 
1.10 SNP in the IL-10 promoter 
A number of polymorphisms of the IL-IO gene promoter have been described. 
There are 3 well-studied single nucleotide polymorphic positions in IL-10 gene 
promoter that are related to the secretion of IL-10. These SNPs are located al 
positions -1087 (A/G), -824 (T/C) and -597 (A/G) upstream of the coding region. 
These three dimorphisms exhibit strong linkage disequilibrium and occur in three 
putative haplotypes: ACC (A at position -1087; C at -824 and -597), ATA and GCC 
(Eskdale and Gallagher, 1995). 
In vitro stimulation of peripheral blood lymphocytes using concanavalin A 
revealed that the -1087 GG allele is associated with 1.3 fold increase in IL-10 protein 
production compared to the low IL-lO-producing AA genotype (Eskdale and 
Gallagher, 1995). The GCC haplotype also exhibits significantly higher 
transcriptional activity than the ATA haplotype in a luciferase reporter system 
(Crawley et al, 1999). In lymphoma, genetic variation of the ILIO- promoter may 
also be related to IL-10 production. IL-10 might be produced by both the lymphomas 
as well as the bystander reactive cells. The IL-10 serum levels reflect the tumor 
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burden and the host-tumor relationship. (Benjamin et al, 1992; Emilie et al, 1992). In 
vitro studies revealed that IL-10 production could be related to its gene promoter 
polymorphisms in lymphoma (Turner et al, 1997). Several studies performed in 
different ethnic groups indicated that distinct IL-10 alleles or haplotypes are a key 
1 actor of IL-10 production in vivo (Eskdale et al, 1997; Lim et al, 1998; Cavet et al, 
1999; Helminen et al, 1999). These observations raise the possibility that 
susceptibility and clinical course of disorders in which immune activation plays an 
important pathogenic role could be related to the genetic control oHL-lO production. 
1.11 IL-10 promoter SNP in DLBCL 
The role of ILIO, SNP in IL-10 promoters and outcomes of DLBCL remains 
controversial. The IL-10 SNP -1087G allele is associated with DLBCL as compared 
with the ethnically matched healthy control group in a French series involving 199 
patients. The presence of the IL-10 -1087G allele may contribute to the genetic 
background of DLBCL occurrence (Lech-Maranda et al, 2004). This IL-10 -1087G 
was previously found to be associated with high IL-10 producing capability (Eskdale 
et al, 1997; Lim et al, 1998; Hulkkonen et al, 2001). Increased IL-10 production 
within tumor microenvironment might be of protective value to the tumor cells. 
IL-10 strongly inhibited the prolil^ration of T-cell clones via its downregulalory 
37 
effects on APC function (Moore et al, 2001). This may fecilitate the tumor cell in 
escaping from the immune system. IL-10(-1087G) allele is noted to be an 
independent variable, predicting longer freedom from progression in DLBCL with 
matched IPI. On the other hand, in a Sweden series, involving 168 primary DLBCL 
and 67 secondary DLBCL, such observation for elevated serum IL-10 cannot be 
confirmed (Berglund et al, 2005). 
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Chapter 2: Aims of Study 
Background: 
SNPs at the IL-10 promoter positions -597, -824 and -1087 are related to the 
serum level of IL-10. IL-10 is an important immuno-regulalory cytokine of B-cells, 
and plays an important role in immunosuppression of proinflammatory T-cell. 
DLBCL is the most common type of non-Hodgkin's Lymphoma (NHL), comprising 
30-40% of NHL cases worldwide. Subtyping of DLBCL according to gene 
expression at the mRNA and protein levels is of prognostic significance. The 
relationship of SNP of IL-10 promoter, subtypes of DLBCL and prognosis in the 
local population are not fully understood. 
Objcctivc of the study: 
The aim of this project is to investigate the association of the IL-10 promoter 
SNPs with NHL and DLBCL. The IL-10 promoter SNPs in specific subtypes of 
DLBCL is investigated. The prognostic values of in the overall survival of DLBCL. 
1. To study the SNP profile in IL-10 promoter at position -597, -824 and -1087 
in normal control, NHL patients and DLBCL patients. 
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2. To sub-classify the archival DLBCL cases by immunohistochemistry. 
3. To study the association of DLBCL biomarkers and each IL-IO promoter SNP 
with overall survival analysis. 
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Chapter 3: Materials and Methods 
3.1 Sample Recruitment 
Recruitment of subjects followed the guidelines of local ethical committee and 
ethical approvals were obtained when required. One hundred and thirty-nine buffy 
coats from the health blood donors were obtained from the Hong Kong Red Cross for 
this study in 2003. A total of 144 non-Hodgkin's lymphoma (NHL, from 1987 to 
2003) and 108 specimens of diffuse large B-cell lymphoma (DLBCL, from 1995 to 
2005) with formalin-fixed, paraffin-embedded archival blocks in the Prince of Wales 
Hospital, Shatin, Hong Kong, were recruited for this study. The diagnosis of each 
patient were histologically reviewed and confirmed independently by three 
histopathologists. 
3.2 DNA preparation for Single Nucleotide Polymorphism (SNP) analysis 
3.2.1 Isolation of Peripheral Blood Mononuclear Cell (PBMC) from buffy coat 
from blood of normal control group 
Mononuclear cells, which contain genomic DNA, were isolated by PBMC 
purification method. Briefly, the buffy coat was diluted with an equal volume of PBS 
and then overlaid on one-third volume of Ficoll-Paqiie Plus, density 1.077 
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(Amersham Biosciences, UK). The buffy coat was centrifiiged at 400x g for 30 
minutes at room temperature. The mononuclear cells from the interface were 
collected and washed with 10ml of PBS twice, by centril\iging at 60x g, to remove 
the platelets. The cell number and the viability were determined by trypan blue 
exclusion test. 
3.2.2 Preparation for NHL and DLBCL samples from paraffin-embedded 
sections for DNA extraction 
Ten 20|.im-sections of each block was cut and collected into 1.5ml eppendoiY 
microcentrifuge lube. The paraffin sections were then de-waxed by washing with 
1.2ml xylene twice, then centrifuged at 13,000 rpm for 5 minutes. After removing the 
supernatant, the pellet was washed with 1.2ml 100% ethanol twice to remove the 
remaining xylene, then centrifuged at 13,000 rpm for 5 minutes and the supernatant 
was removed. The pellet was air-dried at 37°C for 15 minutes. 
3.2.3 DNA extraction for SNP analysis 
DNA was extracted from de-waxed paraffin sections or PBMC isolated from 
bulTy coat of healthy donors using a standard phenol-chloroform method (Sambrook 
et at, 2001). The specimens were digested with Img/ml proteinase K and 2% (w/v) 
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SDS in STE buffer at 56°C. DNA was then extracted with an equal volume of 
24:25:1 phenol:chloroform:isoamy-alcohol (Amresco, Solon, OH). After 
centriliigalion, DNA from the aqueous layer was precipitated with 3 volumes of 
100% elhanol and one-third volume of 3M sodium acetate solution, pH 4.2. The 
precipitation was carried out at -20°C overnight. The precipitated DNA was 
centrifuged at 13,000 rpm in a micro-centrifuge at room temperature. After 
discarding the supernatant, the DNA pellet was washed once with 75% ethanol and 
air-dried. The pellet was resuspended in 50(.il TE solution at 56°C for 1 hour. The 
amount of DNA was quantified using Beckman DU650 spectrophotometer. The 
concentration (|ig/|il) of DNA was calculated by: OD260 x dilution factor x 50/1000. 
3.3 SNP analysis by Restriction Fragment Length Polymorphism (RFLP) 
3.3.1 Aiiiplificatioii of target site by PCR 
The genotype of both the patients and normal controls in IL-IO promoter SNP 
positions -1087, -824 and -597 was analyzed by PCR followed by restriction 
fragment length polymorphism. The primers were designed with the web-based 
so 11 ware "primer3" (htlpi/Zlrodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi; 
Table 3.1). PCR reaction was carried out using AmpliTaq Gold reagents (Applied 
Biosystems, Foster City, CA). In each reaction, Ipi of DNA was added to PCR 
r 
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mixture containing IX reaction buffer II (lOmM Tris-Cl pH 8.3 and 500mM KCl), 
200nM of each of the primer, 2.5mM MgCb, lU AmpliTaq Gold and 200|_iM each of 
dATP, dCTP, dGTP and dTTP (Amersham Bioscience, UK) in 25|.il final reaction 
volume. The PGR thermocycling was carried out using a GeneAmp9700 PGR system 
(Applied Biosystems, Foster City, CA). The reaction was heated to 95°C for 10 
minutes, followed by cycling at 95°C for 30 seconds, 55°C lor 30 seconds and 72°C 
for 60 seconds for 40 cycles. The PGR product was resolved in 2% agarose gel in 
TBE. The gel was then stained with ethidium bromide and visualized under UV 
illumination. 
Primer Amplicon 
Direction Sequence (5'-3') 
Name size (bp) 
Forward AAT GAA ATC GGG GTA AAG GA 
IL-10(597) 150 
Reverse CCT TAG TTT CCC CAA GTA AA 
Forward GAA ACC AAA TTC TCA GTT GG 
1L-10(824) 150 
Reverse GTC TGC ACT TGC TGA AAG CT 
IL-10 Forward CAA GAC AAC ACT ACT AAG GCT TCT T 
100 
(1087) Reverse GTC CCT TAC TTT GCT CTT ACC TAT C 
Table 3.1 Primer sequences for Restriction fragment length polymorphism. 
44 
3.3.2 SNP analysis 
The target sequence of -1087, -824 and -597 in IL-10 promoter were analyzed 
by a web-based software "NEBciitler v2.0" 
(hltp://tools.neb.com/NEBciitter2/index.php) to check for the suitable restriction 
endonucleases for each position. Three restriction endonucleases were used to 
perform RFLP in the IL-10 promoter SNP analysis, namely, Mill I (New England 
Biolabs, Beverly) for position -1087 (A/G), Mae III (Roche Applied Science, 
Penzberg, Germany) for position -824 (T/C) and Rsa I (Roche Applied Science, 
Penzberg, Germany) for position -597 (A/C). The recognition sequence of each 
restriction eiidonuclease is listed in Table 3.2. 
Restriction Cutting Recognition Working 
Endonuclcase genotype sequence temperature 
5，...CCTT(N)7 八...3’ ， � � 广 
Mill I -1087G V n C 
3'...GGAA(N)6^...5' 
5 ' . . .GT^AC.. .3 ' … 
Mae III -824C 55 C 
3,...CAATG...5’ 
5，...AGTNAC …3' � … 
Rsa I -597A 37 C 
3,……CANTG^.. .5 ' 
Tabic 3.2 The recognition sequences and working temperatures of restriction 
endonucleases for RFLP 
The PCR products underwent restriction digestion by specific restriction 
eiidonuclease for each IL-10 promoter SNP position. For position -1087, in each 
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reaction, 1 OpJ of PCR product was added to restriction digestion mixture containing 
IX NEBulTer 2 (lOmM Tris-HCl, 50mM NaCi, lOmM MgCl2 and ImM 
Dithiothreilol, pH 7.9), 100|ig/ml BSA and lU Mnl I in 20|.il final reaction volume. 
The reaction mixture was then incubated at 37°C water bath overnight. For position 
-824, in each reaction, 10|il of PCR product was added to restriction digestion 
mixture containing IX incubation buffer (20mM Tris-HCl, 275mM NaCl, 6mM 
MgCb and 7mM 2-Mercaptoethanol pH 8.2) and lU Mae III in 25|il final reaction 
volume. The reaction mixture was then incubated at 55°C water bath overnight. For 
position -597, in each reaction, 10|il of PCR product was added to restriction 
digestion mixture containing IX SuRE/Cut Buffer L (lOmM Tris-HCl, 1 OmM MgCb 
and ImM Dithioerythritol pH 7.5) and lU Rsa I in 20|al final reaction volume. The 
reaction mixture was then incubated at 37°C water bath overnight. The restriction 
digested products were resolved in 10% polyacrylamide gel in TBE, stained with 
elhidium bromide and then visualized under UV illumination. Fig 2.1 shows the 
electrophoresis profile of different genotypes at position -597, Rsa I will cut at -597 
A-allele to form 2 fragments with 50bp and lOObp. For position -824, Mae III will 
cut in the same electrophoresis profile will be obtained, while for position -1087, the 
fragments will be cut in 75bp and 25bp by Mnl I. The electrophoresis profile is 
shown in Fig. 2.2 and 2.3 respectively. 
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C C A C A A 
Fig 2.1 Electrophoresis profile of genotypes at -597 
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C C T C T T 
Fig 2.2 Electrophoresis profile of genotypes at -824 
48 
A G A A 
• 
Fig 2.3 Electrophoresis profile of genotypes at -1087 
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3.4 Determination of haplotypic frequency 
The haplotypic frequency of IL-10 promoter was determined by software called 
"EH". The frequency of all possible haplotypes was input into this software, and the 
haplolypic Frequency was calculated. 
3.5 Classification of DLBCL by iinmunohistochcmistry 
In order to classify different subtypes of DLBCL, immunohistochemistry was 
performed by staining with 4 different antibodies against CDIO, Bcl-6, CD 138 and 
MUM1/IRF4 (Chang et al, 2004). Briefly, 4^m-sections of each sample was cut and 
mounted on a Lysine-A coated glass slide. The section was deparalTinized in xylene 
for 3 minutes twice following by rehydration through graded alcohol (100% elhanol, 
95% elhanol) and finally distilled water, 3 minutes for each step. 
Antigen retrieval was performed using high temperature antigen unmasking 
method under microwave. Slides after rehydration were put into ImM Citrate Buffer. 
Slides were then heated in a domestic microwave (Panasonic, 800W) oven twice, 
using Power 10 (800W) for 3 minutes and then Power 3 (250W) for 10 minutes. 
After microwave treatment, slides were cooled down for 30 minutes under room 
temperalure to prevent the detachment of section from glass slide. 
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After antigen retrieval, the slides were pretreated in 0.3% H2O2 for 10 
minutes to block the endogenous peroxidase by substrate-inhibition. Slides were then 
washed for three times with TBS for 5 minutes. Slides were then blocked with 5% 
v/v normal rabbit serum for 10 minutes. Excess normal rabbit serum was removed 
after blocking, and replaced by primary mouse anti-human antibody, anti-CD 10 
(Zymed Laboratories, South San Francisco, CA), anti-Bcl-6 (DakoCytomation, 
Denmark), anti-CD 138 (DakoCytomation, Denmark) and 
anti-MUMl/lRF4(DakoCytomation, Denmark), diluted in TBS with 0.3% BSA with 
dilution of 1:100. The slides were incubated at room temperature overnight. 
After incubation, slides were washed three times with TBS for 5 minutes. 
Biotinylated rabbit anti-mouse secondary antibody (DakoCytomation, Denmark), 
diluted 1:200 in TBS with 0.3% BSA, was added to the slides and then incubated for 
30 minutes at room temperature. Slides were then washed with TBS three times for 5 
minutes. 
Slreptavidin-HRP (Zymed Laboratories, South San Francisco, CA), diluted in 
1:400 with TBS and 0.3% BSA, were added to slides and incubated for 45 minutes at 
room temperature. The slides were then washed with TBS three times for 5 minutes. 
3，3’-Diaminobeiizidine (DAB) development was performed by adding DAB solution 
which contain 0.2ml 2.5% DAB dissolved in 10ml TBS with 0.3% H2O2. DAB 
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development lasted for 10 minutes, and brown color was observed for positive 
staining. After DAB development, the slides were counterstained with Haematoxylin. 
The slides were dehydrated through graded alcohol (95% elhanol and then 100% 
elhanol), and finally in xylene for 3 times, 3 minutes for each step. The slides were 
mounted and ready for scoring. 
Immunohistochemical stained slides were independently scored by 3 
investigators Dr. Anthony Lo, Dr. Amy Chan and me. Immunohistochemical 
stainings for each of the antibodies were positive if more than 20% of the lymphoma 
cells showed the expected patterns of staining. The staining intensity was not 
included in the diagnosis of positivity. Conflicts of interpretation between 
investigators were resolved with resolution by the aid of multi-head microscope. 
Siibtyping of DLBCL follows Table 1.1 in the Introduction. 
52 
3.5.4 Staining pattern of MUM1/IRF4 
A membranous staining pattern is observed and this staining pattern is usually 
homogenous throughout the tumour. Fig 3.1. 
� J d ‘ ？ 
〜 - , , ， / 二 
Figure 3.1 Positive membranous staining of CD 10 in DLBCL 
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3.5.4 Staining pattern of MUM1/IRF4 
A nuclear staining is obtained by immunohistochemistry. Fig. 3.2. 
Figure 3.2 Positive nuclear staining of Bcl-6 in DLBCL 
54 
3.5.4 Staining pattern of MUM1/IRF4 
Expression of CD138 shows a cytoplasmic/membranous staining pattern by 
immunhistochemistry. Fig. 3.3. 
m 
Figure 3.3 Positive cytoplasmic/membranous staining of CD 138 in DLBCL 
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3.5.4 Staining pattern of MUM1/IRF4 
Expression of MUM1/IRF4 shows a cytoplasmic/nuclear staining pattern by 
immunhistochemistry. Fig. 3.4. 
_ 
Figure 3.4 Positive cytoplasmic/nuclear staining of MUM1/IRF4 in DLBCL. 
56 
3.6 Statistical Analysis 
Chi-square test was applied for the statistical analysis in IL-10 promoter SNP 
study for sample size larger than 5. For those group which the sample size less than 5, 
Fisher exact test was used to calculate the p value. The data was processed using 
Statistical Package for Social Science (SPSS) vlO.l. A p value less than 0.05 was 
considered lo be statistically significant. Cox Proportional Hazards Regression 
• 
Analysis was also processed by SPSS vlO.l for the overall survival analysis of -
DLBCL patients. 
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Chapter 4: Results 
4.1 SNPs of IL-10 promoter in normal controls 
4.1.1 Allelic Frequencies and genotype distributions 
The buffy coals were collected from the Hong Kong Red Cross in the year 2003. 
All subjects were anonymous. No epidemiological information was available, except 
that all the specimens were IVoni the local Chinese donors in Hong Kong. The allelic 
frequencies and genotypes distribution at positions -1087，-824 and -597 of the IL-10 
promoter in 139 normal healthy controls are shown in Table 4.1. The most common 
alleles at the IL-10 promoter were -1087 A (97.48%)，-824 T (70.14%) and -597 A 
(70.14%). The most common genotypes at IL-10 promoter positions -1087, -824 and 
-597 were AA (94.96%), TT (51.08%) and AA (51.08%), respectively. Interestingly, 
the genotypes at positions -824 and -597 are closely linked. The -824 T-allele was 
followed by -597 A-allele; and -824 C-allele was followed by -597 C-allele. No 
linkage was observed in position -1087 with the other two positions. 
4.1.2 Haplotypic Frequencies of normal controls 
The haplotypic frequencies of IL-10 promoter in 139 normal controls are shown 
in Table 4.2. Four haplotypes were observed: ATA (69.78%), ACC (27.70%), GCC 
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(2.16%) and GTA (0.36%). The halpotypes ATC, ACA, GTC and GCA were not 
detected in this control group. 
4.2 SNP of the IL-10 promoter in non-Hodgkin's lymphomas 
4.2.1 Allelic frequencies and genotype distributions 
The allelic frequencies and genotype distributions at position -1087，-824 and 
-597 of IL-10 promoter in normal healthy control group and 144 NHL patients are 
shown in Table 4.1. NHL patients had the same common alleles and similar allelic 
frequencies. The specific genotypes encountered and the distribution in NHL was the 
same as those of the normal controls. As shown by the Chi-square test, both allelic 
frequencies and genotype distributions of NHL patients were not statistically 
dilTerencl from those of the normal control. 
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Control (11=139) NHL (n=144) /;-va[ue^' 
Allclic Frequencies 
IL-10.,o87G 2.52% 3.47% 0.339 
IL-10 .,087A 97.48% 96.53% 0.339 
IL-10 .8241 70.14% 73.38% 0.857 
IL-10 .824C 29.86% 26.62% 0.857 
IL-10 .597 A 70.14% 73.38% 0.857 
IL-10 .597C 29.86% 26.62% 0.857 
Genotype Distributions (%) 
IL-10-,()87(IG 0 (0.00%) 0 (0.00%) N/A 
IL-10 .,087GA 7 (5.04%) 10 (6.94%) 0.499 
IL-10 _U)87AA 132 (94.96%) 134 (93.06%) 0.499 
IL-10 .824TT 71 (51.08%) 69 (47.92%) 0.595 
IL-10 .824TC 53 (38.13%) 66 (45.83%) 0.189 
IL-10.824CC 15 (10.79) 9 (6.25%) 0.170 
1L-10 . 5 9 7 A A 71 (51.08%) 69 (47.92%) 0.595 
IL-10 .597AC 53 (38.13%) 66 (45.83%) 0.189 
IL-10 .597CC 15 (10.79) 9 (6.25%) 0.170 
Table 4.1 Allelic frequencies and genotype distributions of IL-LO-iosv, IL-10.824 and 
IL-10.597 polymorphisms in 139 normal healthy controls and 144 NHL patients. 
A Chi-square test comparing the normal controls and NHL. A p-value of <0.05 is 
considered significant. 
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4.5.1.2 Haplotypic frequencies 
The haplotypic frequencies of lL-10 promoter in 139 normal controls and 144 
NHL patients are shown in Table 4.2. The four haplotypes found in the normal 
subjects were also observed in the NHL patients. No unique halpotype was detected 
in NHL. The frequency of each halpotype was similar in both NHL and control. As 
shown by Chi-square test, there were no significant differences between normal 
control and NHL patients. 
Control (n二 139) NHL(n=144) /—value" 
Haplotypic Frequencies 
ATA 194 (69.78%) 203 (70.49%) 0.566 
ATC 0 0 
ACA 0 0 
ACC 77 (27.70%) 75 (26.04%) 0.657 
GTA 1 (0.36%) 1 (0.35%) 1.000 
GTC 0 0 
GCA 0 0 
GCC 6(2.16%) 9(3.13%) 0.474 
Table 4.2 Haplotypic frequencies of IL-10 promoter in 139 normal controls and 144 
NHL patients. 
“Chi-square test comparing the normal controls and NHL. A p-value of <0.05 is 
considered significant. 
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4.4 SNPs of the IL-10 promoter in DLBCL 
4.4.1 Allclic frequencies and genotype distributions 
108 DLBCL cases were collected retrospectively from the formalin-fixed, 
paraffin-embedded archival sections. Among these samples, there are 53 males and 
55 females. The mean age was 61.51 years. 
The allelic frequencies and genotype distributions at position -1087, -824 and 
-597 of the IL-10 promoter in normal healthy control group and 108 DLBCL patients 
are shown in Table 4.3. There were no significant difference between the allelic 
frequencies in DLBCL patients and normal control in all the three SNP positions. In 
DLBCL, the most common genotypes at positions -1087 and -597 were AA (97.22%) 
and AA (48.15%). However, no significant differences were found in the genotype 
distributions between normal control and DLBCL in these two positions. On the 
other hand, the most common genotype of DLBCL at position -824 was TC (57.41%), 
which was different from the normal control. Moreover, significant differences were 
observed in the genotypes at these positions between DLBCL and normal by 
Chi-square test: IL-10.824TT (P = 0 . 0 1 9 ) and IL-10.824 RC (P = 0 . 0 0 3 ) . Furthermore, 
unlike the case of normal controls, the genotypes of DLBCL at position -824 were 
not always linked with those at position -597. 
62 
Control (11=139) DLBCL (ii=108) /7-valuc" 
Allclic Frequencies 
IL-10 .,087G 2.52% 1.85% 0.619 
I L - 1 0 .1087A 嫩 9 7 ^ 4 8 % 9 8 . 1 5 % 0.619 
IL-10 .824T 70.14% 64.81% 0.209 
IL-10 .824C 29.86% 35.19% 0.209 
IL-10 .597A 70.14% 69.91% 0.955 
1L-10 .597C 29.86% 30.09% 0.955 
Genotype Distributions (%) 
IL-10-,()87GG 0 (0.00%) 1 (0.93%) 0.256 
IL-10 .1087GA 7 (5.04%) 2(1.85%) 0.185 
IL-10-1087AA 132 (94.96%) 105 (97.22%) 0.372 
IL-10.824TR 71 (51.08%) 39 (36.11%) 0.019* 
IL-10 .824-,C 53 (38.13%) 62 (57.41%) 0.003* 
IL-10.824CC 15 (10.79) 7 (6.48%) 0.238 
IL-10 .597AA 71 (51.08%) 52 (48.15%) 0.648 
IL-10 .597AC 53 (38.13%) 47 (43.52%) 0.392 
I L - 1 0 .597CC 15 ( 1 0 . 7 9 ) 9 ( 8 . 3 3 % ) 0 . 5 1 8 
Table 4.3 Allelic frequencies and genotype distributions oflL-lO.iosv, IL-10.824 and 
IL-10.597 polymorphisms in 139 normal healthy controls and 108 DLBCL patients. 
a Chi-square test comparing the normal controls and DLBCL. A p-value of <0.05 is 
considered significant (*)• 
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4.5.1.2 Haplotypic frequencies 
The haplotypic frequencies of the IL-IO promoter in 139 normal controls and 
108 DLBCL patients are shown in Table 4.4. Besides the haplotypes ATA, ACC, 
GTC and GCC that were also observed in normal controls, haplotypes ATC, ACA 
1 
and GCA were also detected in patients with DLBCL. As shown in Chi-square test, 
significant differences was obtained in haplotypes ACA (p = 0.000). 
Control (n=139) DLBCL (n=108) /;-valuc^ 
Haplotypic Frequencies 
ATA 194 (69.78%) 136 (62.96%) 0.089 
ATC 0 2 (0.93%) 0.191 
ACA 0 12(5.56%) 0.000 * 
ACC 77 (27.70%) 62 (28.70%) 0.894 
GTA 1 (0.36%) 1 (0.46%) 1.000 
GTC 0 0 N/A 
GCA 0 1 (0.46%) 1 
GCC 6(2.16%) 4(15.38%) 1.000 
Table 4.4 Haplotypic frequencies of IL-IO promoter in 139 normal controls and 108 
DLBCL patients. 
a Chi-square test comparing the normal controls and DLBCL. A p-value of <0.05 is 
considered significant (*). 
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4.5 SNP of the IL-10 promoter in different subtypes of DLBCL 
4.5.1 Classification of DLBCL by immunohistochemistry 
DLBCL were subclassified into different subtypes according to the 
immunohistochemical slainings of antibodies against CDIO, Bcl-6, CD 138 and 
MUMl (Table 1.1 in Introduction). There were 23 cases positive for CDIO; 41 cases 
positive for Bcl-6; 25 cases positive for CD 138 and 94 cases positive for MUMl 
(Table 4.5). The frequency of each subtypes of DLBCL is shown in Table 4.6. The 
most common subtype of DLBCL was activated non-germinal center DLBCL which 
comprised 60 cases (55.56%). Germinal center DLBCL was rare in the local series. 
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Antigens Positive (%) Negative (%) 
CDIO 23 (21.30%) 85 (78.70%) 
Bcl-6 41 (37.96%) 67 (62.04%) 
CD138 25 (23.15%) 83 (76.85%) 
MUMl 94 (87.04%) 14(12.96%) 
Table 4.5 Immunohistochemical results with antibodies against CDIO, Bcl-6, CD 138 
and MUMlof 108 DLBCL patients. 
DLBCL Subtypes Frequency Percentage 
Germinal Center 9 8.33% 
Activated Germinal Center 28 25.93% 
Activated non-Germinal Center 60 55.56% 
Unclassified 11 10.19% 
Total 108 100% 
Table 4.6 Frequencies of DLBCL subtypes using immunohistochemical 
classification by 4 antibodies against CDIO, Bcl-6, CD138 and MUMl. 
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4.5.2 SNP of the IL-10 promoter in Germinal Center DLBCL (GC-DLBCL) 
4.5.2.1 Allelic frequencies and genotype distributions 
There were 9 DLBCL patients classified as GC-DLBCL. The allelic frequencies 
and genotype distributions at positions -1087, -824 and -597 of the IL-10 promoter in 
normal control group and 9 GC-DLBCL patients are shown in Table 4.7. As shown 
by Chi-square test, there were no significant differences in allelic frequencies 
between GC-DLBCL patients and normal control. However, in genotype 
distributions，significant differences were found in IL-10 _824tt (p = 0.034) and IL-10 
- 8 2 4 T C ( P = 0.004). 
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Control (n=139) GC-DLBCL (n=9) />valuc" 
Allclic Frequencies 
IL-10.I()87G 2.52% 0.00% 0.496 
IL-10.,o87A 9 7 . 4 8 % 100.00% 0.496 
IL-10 .824T 70.14% 55.56% 0.194 
IL-10 .824C 29.86% 44.44% 0.194 
IL-10 _597A 70.14% 72.22% 0.852 
IL-10 .597C 29.86% 27.78% 0.852 
Genotype Distributions (%) 
I L - 1 0 .,087GG 0 ( 0 . 0 0 % ) 0 ( 0 . 0 0 % ) N / A 
I L - 1 0 _1087GA 7 ( 5 . 0 4 % ) 0 ( 0 . 0 0 % ) 0 . 4 9 0 
IL-10 .,087AA 132(94.96%) 9(100.00%) 0.490 
IL-10 -824TT 71 (51.08%) 8 (88.89%) 0.034* 
IL-10 .824TC 53 (38.13%) 1(11.11%) 0.004 * 
IL-10 .824CC 15 (10.79) 0 (0.00%) 0.599 
I L - 1 0 .597AA 71 ( 5 1 . 0 8 % ) 4 ( 4 4 . 4 4 % ) 0 . 7 0 0 
I L - 1 0 .597AC 5 3 ( 3 8 . 1 3 % ) 5 ( 5 5 . 5 6 % ) 0 . 2 9 9 
IL-10.597CC 15 (10.79) 0 (0.00%) 0.599 
Tabic 4.7 Allelic frequencies and genotype distributions of IL-10.losv, IL-10.824 and 
IL-10.597 polymorphisms in 139 normal healthy controls and 9 GC-DLBCL patients. 
a Chi-square test comparing the normal controls and DLBCL. A p-value of <0.05 is 
considered significant (*). 
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4.5.1.2 Haplotypic frequencies 
The haplotypic frequencies of the IL-10 promoter in 139 normal controls and 9 
GC-DLBCL patients are shown in Table 4.8. As shown in the table by Chi-square 
test, significant difference was found for haplotype ACA (p < 0.001). 
Haplotypic Frcqucncics Control (n=139) GC-DLBCL (n=9) p-valiie" 
194 (69.78%) 10 (55.56%) 0.206 
ATC 0 0 N/A 
ACA 0 3 (16.67%) 0.000* 
ACC 77 (27.70%) 5(27.77%) 0.994 
GTA 1 (0.36%) 0 0.798 
GTC 0 0 N/A 
GCA 0 0 N/A 
GCC 6(2.16%) 0 0.525 
Table 4.8 Haplotypic frequencies of IL-10 promoter in 139 normal controls and 9 
GC-DLBCL patients. 
“Chi-square test comparing the normal controls and DLBCL. A p-valiie of <0.05 is 
considered significant (*). 
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4.5.2 SNP of the lL-10 promoter in Activated Germinal Center DLBCL 
(AGC DLBCL) 
4.5.2.1 Allelic frequencies and genotype distributions 
There were 28 DLBCL patients classified as AGC-DLBCL. The allelic 
frequencies and genotype distributions at positions -1087, -824 and -597 of the IL-IO 
promoter in normal control group and 28 AGC-DLBCL patients are shown in Table 
4.9. As shown in the table by Chi-square test, there were no significant differences 
between normal and AGC-DLBCL patients in both allelic frequencies and genotype 
distributions. 
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Control (n=139) AGC-DLBCL (ii=28) /;-vaIue" 
Allclic Frequencies 
IL-10 -,087G 2.52% 3.57% 0.657 
IL-10 .,087A 97.48% 96.43% 0.657 
IL-10 .824T 7 0 . 1 4 % 62.50% 0.260 
I L - 1 0 .824C 2 9 . 8 6 % 3 7 . 5 0 % 0 . 2 6 0 
I L - 1 0 .597A 7 0 . 1 4 % 6 7 . 8 6 % 0 . 7 3 4 
I L - 1 0 .597C 2 9 . 8 6 % 3 2 . 1 4 % 0 . 7 3 4 
Genotype Distributions (%) 
IL-10 .,()87GG 0 (0.00%) 0 (0.00%) N/A 
I L - 1 0 .1087GA 7 ( 5 . 0 4 % ) 2 ( 7 . 1 4 % ) 0 . 6 5 2 
IL-10-I()87aa 132 (94.96%) 26 (92.86%) 0.652 
IL-10 -824TT 71 (51.08%) 10 (35.72%) 0.138 
IL-10 .824TC 53 (38.13%) 15(53.57%) 0.129 
IL-10 .824CC 15 (10.79) 3 (10.71%) 1.000 
I L - 1 0 .597AA 71 ( 5 1 . 0 8 % ) 13 ( 4 6 . 4 3 % ) 0 . 6 5 3 
IL-10 .597AC 53 (38.13%) 12 (42.86%) 0.640 
IL-10.597CC 15 (10 .79 ) 3 ( 1 0 . 7 1 % ) 1 .000 
Table 4.9 Allelic frequencies and genotype distributions of IL-lO.ios?, IL-10.824 and 
IL-10.597 polymorphisms in 139 normal healthy controls and 28 AGC-DLBCL 
patients. 
A Chi-square test comparing the normal controls and DLBCL. A p-value OF <0.05 is 
considered significant (*). 
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4.5.1.2 Haplotypic frequencies 
The haplotypic frequencies of IL-10 promoter in 139 normal controls and 28 
AGC-DLBCL patients are shown in Table 4.10. As shown by Chi-square test, 
significant difference was found in haplolype AC A (p = 0.028). 
Control (n=139) AGC-DLBCL (n=28) /;-vaIuc" 
Haplotypic Frequencies 
ATA 194 (69.78%) 34 (60.71%) 0.183 
ATC 0 0 N / A I 
ACA 0 2 (3.57%) 0.028* 
ACC 77 (27.70%) 1?(32.14%) 0.501 
GTA I (0.36%) 1 (1.79%) 0.308 
GTC 0 0 N/A 
GCA 0 1 (1.79%) 0.168 
GCC 6(2.16%) 0 0.525 
Tabic 4.10 Haplotypic frequencies of IL-10 promoter in 139 normal controls and 28 
AGC-DLBCL patients. 
a Chi-square test comparing the normal controls and DLBCL. A p-value of <0.05 is 
considered significant (*). 
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4.5.3 SNP of the IL-10 promoter in Activated non-Germinal Center DLBCL 
(ANGC-DLBCL) 
4.5.3.1 Allelic frequencies and genotype distributions 
There were 60 DLBCL patients classified as ANGC-DLBCL. The allelic 
frequencies and genotype distributions at positions -1087, -824 and -597 of IL-10 
promoter in normal control group and 60 ANGC-DLBCL patients are shown in Table 
4.11. As shown in the table by Chi-square test, there were no significant differences 
between ANGC-DLBCL patients and normal control in allelic frequencies. However, 
significant difference was found in the genotype IL-10 _ 8 2 4 t c (P = 0 . 0 2 7 ) . 
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Control „ 
ANGC-DLBCL (n=60) /7-valuc'' 
(n=139) 
Allclic Frequencies 
IL-10 -1087G 2.52% 1.67% 0.729 
IL-10 .1087A 97.48% 98.33% 0.729 
I L - 1 0 .824T 7 0 . 1 4 % 6 7 . 5 0 % 0 . 6 0 0 
IL-10 .824C 29.86% 32.50% 0.600 
I L - 1 0 .597A 7 0 . 1 4 % 7 0 . 0 0 % 0 . 9 7 7 
IL-10 .597C 29.86% 30.00% 0.977 
Genotype Distributions (%) 
I L - 1 0 .1087GG 0 ( 0 . 0 0 % ) 1 ( 1 . 6 7 % ) 0 . 3 0 2 
I L - 1 0 .1087GA 7 ( 5 . 0 4 % ) 0 ( 0 , 0 0 % ) 0 . 1 0 5 
IL-1().IO87AA 132 ( 9 4 . 9 6 % ) 59 ( 9 8 . 3 3 % ) 0 . 4 3 9 
IL-10 .824TT 71 (51.08%) 24 (40.00%) 0.151 
I L - 1 0 .824TC 53 ( 3 8 . 1 3 % ) 33 ( 5 5 . 0 0 % ) 0 . 0 2 7 * 
I L - 1 0 -824CC 15 ( 1 0 . 7 9 ) 3 ( 5 . 0 0 % ) 0 . 2 8 2 
IL-10 .597AA 71 (51.08%) 29 (48.33%) 0.722 
I L - 1 0 -597AC 53 ( 3 8 . 1 3 % ) 2 6 ( 4 3 . 3 3 % ) 0 . 4 9 1 
IL-10.597CC 15 ( 1 0 . 7 9 ) 5 ( 8 . 3 4 % ) 0 . 5 9 7 
Table 4.11 Allelic frequencies and genotype distributions of IL-10.losv, IL-10.824 and 
IL-10-597 polymorphisms in 139 normal healthy controls and 60 ANGC-DLBCL 
patients. 
a Chi-square test comparing the normal controls and DLBCL. A p-valiie of <0.05 is 
considered significant (*). 
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4.5.3.2 Haplotypic frequencies 
The haplotypic frequencies of IL-IO promoter in 139 normal controls and 60 
ANGC-DLBCL patients are shown in Table 4.12. As shown in the table by 
Chi-square test, significant differences was been found in haplotype ACA (p = 
0.002). 
ANGC-DLBCL 
Haplotypic Frequencies Control (n=139) p-value'' 
(n=60) 
^ 194 (69.78%) 79(65.83%) 0.436 
ATC 0 2 (1.67%) 0.090 
ACA 0 5 (4.16%) 0.002* 
ACC 77 (27,70%) 32 (26.67%) 0.832 
GTA 1 (0.36%) 0 1.000 
GTC 0 0 N/A 
GCA 0 0 N/A 
GCC 6(2.16%) 2(1.67%) 1.000 
Tabic 4.12 Haplotypic frequencies of IL-IO promoter in 139 normal controls and 60 
ANGC-DLBCL patients. 
“Chi-square test comparing the normal controls and DLBCL. A p-value of <0.05 is 
considered significant (*)• 
1 
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4.5.4 SNP of the IL-10 promoter in Unclassified DLBCL (UC-DLBCL) 
4.5.4.1 Allclic frequencies and genotype distributions 
There were 11 DLBCL patients that could not be classified as they did not 
express any of the 4 markers used in this study. The allelic frequencies and genotype 
distributions at positions -1087, -824 and -597 of IL-10 promoter in normal control 
group and 11 UC-DLBCL patients are shown in Table 4.13. As shown in the table by 
Chi-square test, there were no significant differences between the UC-DLBCL 
patients and the normal control in both allelic frequencies and genotype distributions. 
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Control (11=139) UC-DLBCL (n=ll) /;-valuc" 
Allelic Frequencies 
IL-10.,(,87G 2.52% 0.00% 1.000 
IL-10 .1087A 97.48% 100.00% 1.000 
IL-10 .824T 7 0 . 1 4 % 63.64% 0.523 
I L - 1 0 .824C 2 9 . 8 6 % 3 6 . 3 6 % 0 . 5 2 3 
IL-10 .597A 70.14% 72.73% 0.798 
I L - 1 0 .597C 2 9 . 8 6 % 2 7 . 2 7 % 0 . 7 9 8 
Genotype Distributions (%) 
I L - 1 0 . , O 8 7 G G 0(0.00%) 0 (0.00%) N/A 
IL-10 _H)87GA 7 (5.04%) 0 (0.00%) 1.000 
IL-10 .,087AA 132 (94.96%) 11 (100.00%) 1.000 
IL-10 .824TT 71(51.08%) 4 (36.36%) 0.347 
IL-10 .824TC 53 (38.13%) 6 (54.55%) 0.283 
I L - 1 0 .824CC 15 (10 .79 ) 1 ( 9 . 0 9 % ) 1 .000 
IL-10 .597AA 71 (51.08%) 6 (54.55%) 0.825 
I L - 1 0 -597AC 53 ( 3 8 . 1 3 % ) 4 ( 3 6 . 3 6 % ) 1 .000 
IL-10.597CC 15 (10 .79 ) 1 ( 9 . 0 9 % ) 1 .000 
Table 4.13 Haplotypic frequencies of IL-10 promoter in 139 normal controls and 11 
UC-DLBCL patients. 
a Chi-square test comparing the normal controls and DLBCL. A p-value of <0.05 is 
considered significant (*). 
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4.5.1.2 Haplotypic frequencies 
The haplotypic frequencies of IL-10 promoter in 139 normal controls and 11 
UC-DLBCL patients are shown in Table 4.14. As shown in the table by Chi-square 
lest, significant difference was found in haplotype ACA (p = 0.005). 
Haplotypic Frequencies Control (ii=139) UC-DLBCL (i i=l l) /;-value" 
ATA 194 (69.78%) 14(63.64%) 0.547 
ATC 0 0 N/A 
ACA 0 2 (9.09%) 0.005* 
ACC 77 (27.70%) 6 (27.27%) 0 .%6 • 
GTA 1(0.36%) 0 1.000 
GTC 0 0 N/A 
GCA 0 0 N/A 
GCC 6(2.16%) 0 1.000 
Table 4.14 Haplotypic frequencies of IL-10 promoter in 139 normal controls and 11 
UC-DLBCL patients. 
a Chi-square test comparing the normal controls and DLBCL. A p-value of <0.05 is 
considered significant (*). 
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4.6 Summary of SNP of the IL-10 promoter in DLBCL subtypes 
We observed that in AGO，ANGC- and UC-DLBCL, the most common 
genotype in IL-10 .824 was heterozygous TC. This was different from the normal 
control in which the common genotype was the homozygous TT. However, in 
GC-DLBCL the most common genotype for IL-10 -824 was also homozygous TT as 
the normal control. 
We observed that there were rare haplotypes, ATC, ACA and GCA, which only 
appeared in DLBCLs (Table 4.15). These haplotypes were not found in other ethnic 
groups, but only in the Chinese population (Hu et al, 2003). In the present series, 
significant difference was only obtained in haplotype ACA among all DLBCL 
subtypes. 
All 
GC-DLBCL AGC-DLBCL ANGC-DLBCL UC-DLBCL DLBCL 
ATC 0 0 2(100.00%) 0 2 
ACA 3 (25.00%) 2(16.67%) 5 (41.67%) 2(16.67%) 12 
GCA 0 1 (100.00%) 0 0 1 
Table 4.15 Summary of frequencies of the rare halpotypes found only in DLBCL. 
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1 
4.7 Overall survival analysis 
4.7.1 Clinical data of DLBCL 
Among the 108 DLBCL patients, the clinical data of 58 de novo DLBCL 
patients were available and were retrieved retrospectively. The clinical data obtained 
included the general demographic data, the survival status, date of diagnosis and date 
of death (Table 4.16). Among these 58 cases, there were 28 males and 30 females 
(M:F 1:1.07). The mean age was 60.29 (range: 16-92). Among these primary 
DLBCLs, 39 (37.20%) cases were located at extra-nodal site and 19 (32.80%) cases 
were nodal diseases. There were twenty-five of the patients have already died and 
their mean survival period is 12.72 months (range: 0-124 months). Among these 
cases, there were 8 (13.80%) positive for CDIO; 23 (39.70%) positive for Bcl-6; 12 
(20.70%) positive for CD138 and 54 (93.10%) positive MUMl. From 
immunohistochemical classification, 2 (3.40%) cases were GC-DLBCL, 22 (37.90%) 
cases were AGC-DLBCL, 33 (56.90%) cases were ANGC-DLBCL and 1 (1.70%) 
cases were unclassified (Table 4.16). 
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DLBCL Subtypes Frequency Percentage 
Germinal Center 2 3.45% 
Activated Germinal Center 22 37.93% 
Activated non-Germinal Center 33 56.90% 
Unclassified 1 1.72% 
Total 58 100% 
Table 4.16 Frequency of DLBCL subtypes in overall survival analysis 
4.7.2 Cox Proportional Hazards Regression Analysis in DLBCL 
Univariate Cox Proportional Hazards Regression Analysis was done to estimate 
the impact of expression of each marker and expression patterns of these markers in 
the primary DLBCL patients (Table 4.17). There were no statistically significant 
impacts on overall survival observed in expression patterns of CDIO, Bcl-6, CD138 
and MUMl as well as the SNPs of IL-IO promoter. 
Further statistical modelings were performed to investigate whether there was 
impact on overall survival of each parameter together with one of the 
immunohislochemical marker. In this analysis, the expressions of CDIO, Bcl-6, 
CD 138 and MUMl were investigated individually in the impact of overall survival. 
The results were shown in Table 4.19-22. There were no significant impacts in each 
parameter, including SNPs of lL-10 promoters and disease sites together with CDIO, 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 5: Discussion 
5.1 SNP for low IL-10 production in Hong Kong population 
In the present study, the predominant allelic frequencies in the Chinese population 
of Hong Kong for IL-10 .1087，IL-10 .824 and IL-10 .597 were A-allele (97.48%), T-allele 
(70.14%) and A-allele (70.14%), respectively. The allelic frequencies of all three 
positions and the frequencies of halpotypes were consistent with earlier reports (Mok et 
al, 1998). Four haplotypes were observed, ATA (70.49%), ACC (26.04%), GCC 
(3.13%) and GTA (0.35%). 
The allelic frequencies, genotype and haplotypes of SNPs in the IL-10 promoter 
varies in ditTerent ethnical population (Reynard et al, 2000). For Caucasian from UK, the 
allelic frequencies of IL-10 - i ( )87a and IL-10 . i o s t g were 51.00% and 49.00% respectively 
(Reynard et al, 2000). Both A and G allele have similar frequency within the UK. 
population. However, in the Oriental population, the allelic frequencies of IL-10 -聽八 
and IL-10 .i087G were 94.00% and 6.00%, respectively (Mok et al, 1998). The A-allele is 
predominant within the Oriental population. In Caucasians, the predominant alleles of 
the positions of IL-10 .824 and IL-10 .597 are both C-allele (77.00%) (Reynard et al, 2000). 
Ill the Oriental population, the predominant allele at IL-10 .824 and IL-10 .597 are T-allele 
(67.00%) and A-allele (67.00%), respectively (Mok et al, 1998). Ethnical difference is 
also observed in halpotypes of the IL-10 promoter. In Caucasians, all three SNP 
positions are grouped together Forming three haplotypes GCC (49.40%), ACC (28.80%) 
and ATA (21.80%) (Reynard el al, 2000). In the Orientals, four haplotypes are formed, 
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they arc GCC (2.00%), ACC (30.00%), ATA (64.00%) and GTA (4.00%) (Mok et al, 
1998). The haplotype GTA is only observed in the Oriental population but not in the 
Caucasians. The most important functional implications of these studies were that the 
genotypes and haplotypes of the IL-IO promoter in Caucasians are responsible for high 
IL-IO production. In contrast, the genotypes and haloptypes of the IL-IO promoters in 
the Chinese population are those of low IL-IO production 
The SNPs ill the human lL-10 promoter affect nuclear factor binding properties and 
influence the IL-IO gene transcription in vitro (Rees, et al, 2002). The IL-IO base 
transition at position -1087 lies within a putative ETS transcription factor-binding site 
(Kube et al, 1995)，however, DNA sequence around -1087 position does not correspond 
to any published ETS consensus binding sites (Wasylyk et al, 1993; Janknecht et al, 
1993; Crepieiix et al, 1994). It was demonstrated that -1087 A-allele has higher affinity 
to ETS transcription factor than that of-1087 G-allele. It was found that the actual ETS 
transcription factor is PlJ.l, which inhibits the gene expression of lL-10 (Reuss et al, 
2002). It has also been demonstrated by the reporter gene assays that particular SNP 
alleles have variable activities (Crawley et al, 1999). Individuals homozygous for 
haplotype ATA produce significantly less IL-IO than those without the ATA haplotype. 
Moreover, in the luciferase reporter assays using the truncated version of IL-IO promoter, 
significantly higher transcriptional activity was observed using the GCC IL-IO 
haplotype construct, compared to that of the ACC and ATA constructs (Crawley et al, 
1999). 
The present study of the SNPs of the IL-IO promoters confirmed the alleles, 
genotypes and haplotypes in the local Chinese population were those responsible for low 
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IL-10 production. The microenvironment in which lymphoma arises created with such a 
background of IL-10 concentration may be different from that in Caucasian population. 
The significance of SNP of the IL-10 promoter in other types of NHL requires further 
investigation. 
I 
5.2 NHL ill low IL-10 production population 
5.2.1 The relationship between IL-10 and NHL 
It has been demonstrated that the serum IL-10 level is elevated in NHL patient, and 
this elevated serum IL-10 level is related to poor prognosis (Blay et al, 1993). The 
biological significance of the unfavorable prognostic value of IL-10 remains unclear. It 
was hypothesized that this unftworable prognosis is related to the immunosuppressive 
properties of IL-10. IL-10 inhibits the antigen-dependent T-cell proliferation by 
downregulating the expression of MHC class 11 on monocytes and macrophages in vitro. 
1 licretbre, the high serum concentration of IL-10 in NHL patients and, possibly, in the 
microenvironment of the tumor site may exert an inhibitory effect on macrophages and 
antigen-specific T-cell response at tumor site. These may contribute to the lymphoma 
progression in vivo. 
5.2.2 Allclic frequencies and haplotype of the IL-10 promoter in NHL 
In 144 NHL patients of our hospital, the predominant allelic frequencies of IL-10 
-1087，IL-10 .824 and IL-10 -597 were A-allele (96.53%), T-allele (73.38%) and A-allele 
(73.38%), respectively. Four haplotypes were also observed: ATA (70.49%), ACC 
(26.04%), GCC (3.13%) and GTA (0.35%). We found no significant differences between 
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the NHL patients and the normal control group in allelic frequencies , genotypes and 
haplotypes. Hence, we have no evidence suggesting that the NHL in our locality is 
associated with genetic predispositions of a high serum IL-IO. In this retrospective study, 
sera of the NHL patients were not available for the assessment of IL-l 0 levels. If serum 
I L-l 0 did elevate in our NHL patients, as shown in other studies, the main determinant 
of the serum IL-J 0 might then not be related to the SNPs of the lL-1 0 promoter. 
A diverged spectrum of lymphomas arising from different cells of origin IS 
classified under the term "NHL", a equally diverged spectrum of clinical behaviors and 
biochemical parameters are to be expected. Further studies should try to focus on the 
correlation of SNP of the IL-J 0 promoters in each specific NHL. A direct assessment of 
the serum levels of IL-l 0 at different stages of the diseases will be helpful in clarifying 
the role of IL-I 0 in NHL. 
5.3 Classification of DLBCL 
5.3.1 Current prognostic analysis 
The International Prognosis Index (JPI) is currently the standard approach to assess 
prognosis in DLBCL (Shipp et al 1993). However, identical IPI groups include patients 
with heterogeneous prognoses, such as low-intermediate and high-intermediate 
categories, with a long term survival of 40-500/0 (Pedersen et ai , 2004). Therefore, novel 
biomarkers might be incorporated into current risk assessment model of prognosis. 
Subtypes of DLBCL with prognostic significance can be identified by the patterns of 
gene expression using DNA microarray analyses or by the patterns of antigen expression 
using immunohistochemical analyses. The latter is a more practical and economical 
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classification strategy of the disease in routine clinical practice. 
5.3.2 DLBCL subtypes distribution in Hong Kong is different from Caucasian 
In the immunohistochemical analyses of DLBCL, we observed differences in the 
spectrum of subtypes of DLBCL in our locality. The overall frequencies of expression 
for CDIO, Bcl-6, CD 138 and MUM1/1RF4 were as follows: 23 (21.30%), 41 (37.96%), 
25 (23.15%) and 94 (84.04%), respectively. When compared to the frequency of 
expression in Chang's studies by Chi-square test, significant differences were observed 
in all 4 antigens: CDIO (p 二 0.035, OR = 0.440，95% CI: 0.203-0.954), CD 138 (p = 
0.034’ OR = 3.715, 95% CI: 1.055-13.079) and MUM1/1RF4 (p < 0.001, OR = 6.104, 
95% CI: 2.673-13.939). 
The frequencies of each subtype of DLBCL were as follows: 9 (8.33%) 
GC-DLBCL, 28 (25.93%) AGC-DLBCL, 60 (55.56%) ANGC-DLBCL and the 
remaining 11 cases (10.19%) were unclassilled. Significant differences were also 
observed for the frequency of each subtype of DLBCL in Chang's studies by Chi-square 
test: GC-DLBCL (p < 0.001, OR = 0.157，95% CI: 0.061-0.404) and ANGC-DLBCL (p 
=0.001，OR = 3.980, 95% CI: 1.767-8.965). 
The above observation suggested that there were ethnical differences in the 
subtypes of DLBCL. ANGC-DLBCL had higher frequency in the local population, and 
the most common subtypes in Chang's series, GC-DLBCL, was rare. 
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5.4 IL-IO and DLBCL 
The relationship between lL-lO and DLBCL remains contradictory. IL-I0 is an 
important immuno-regulatory cytokine produced by healthy as well as neoplastic B-cells, 
acting as an autocrine growth factor. lL-lO plays an important role in controlling the 
balance between cellular and humoral immune system. IL-IO is also a strong 
immunosuppressive cytokine that inhibits the proimflammatory T-cells (Moore et ai , 
200 I: Benjamin et ai, 1992; Rousset et ai , 1992 and Levy and Brouet, 1994). Therefore, 
it was hypothesized that I L-l 0 may adversely affect the prognosis and clinical outcomes 
of DLBCL patients (Lech-Maranda et ai , 2004). Earlier report did not support a 
prognosis correlation between IL-IO and DLBCL (Cortes et ai , 1995). Two further 
reports show contrasting results of lL-l 0 and outcomes of DLBCL (Lech-Maranda et ai , 
2004 and Berglund et aI , 2005), and hence it is hypothesized that increased serum levels 
of 1 L-l 0 reflect an enhanced activation of the immune system on more aggressive 
disease, but its potential action as a growth factor for lymphoma cells or as a suppressor 
of macrophages or T-cell functions (Voorzanger et ai , 1996). 
In this study, there were no significant differences between DLBCL patients and 
normal control in allelic frequencies. Significant differences were, however, observed in 
genotype IL-I 0 -824rr (p = 0.019, OR = 0.541 , 95% Cl: 0.324-0.906) and IL-IO -824TC (p = 
0.003, OR = 2.187, 95% Cl: 1.310-3.651). When comparing IL-IO -824CC, there was no 
significant difference found, suggesting that only the T-allele, which is responsible for 
the low IL-I 0 secretion (Lech-Maranda et ai , 2004), was associated with DLBCL. This 
association of low IL-IO promoter allele has been observed by others in NHL. The 
relative lack of IL-I 0 might alter the immune responses and might allow the lymphoma 
93 
arise or progress under the influence of other pro-lymphoma cytokines (Cunningham et 
al, 2003). 
5.5 SNP of IL-10 promoter in DLBCL subtypes 
5.5.1 Allclic frequencies and haplotype of DLBCL subtypes 
In three subtypes of DLBCL, the allelic frequencies of all the cases were having no 
significant differences from the normal control. However, in GC-DLBCL and 
ANGC-DLBCL, at IL-10 .824 significant differences were observed in TT and TC 
genotypes in GC-DLBCL, whereas TC genotype in ANGC-DLBCL. This suggested that 
the low production T-allele in IL-10 promoter was associated with GC- and 
ANGC-DLBCL patients.. 
5.5.2 Rare haplotypes were discovered in DLBCL 
Besides those typical haplotypes, rare haplotypes, ACA and ATC, were observed 
in the local DLBCL patients. These haplotypes were not observed in normal control. The 
haplotype frequency of ACA in DLBCL was significantly different from the control 
group (p < 0.001, OR = 0.944, 95% CI: 0.914-0.975). These two new haplotypes were 
found in the Chinese but not in the Caucasians (Hu et al, 2003). The relationship 
between the haplotype ACA and IL-10 production, however, has not been studied. 
Further investigation, such as luciferase reporter assay and ELISA in these haplotypes, is 
needed to clarify the relationship between these haplotypes and the secretion of IL-10. 
Whether these haplotypes predisposed to the development of DLBCL or the variations 
ofclinical behaviors of the local DLBCL remains to be resolved. 
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5.6 Overall survival Analysis 
Previous studies revealed that CDIO and Bcl-6 are the markers that are strongly 
associated with the germinal center B-cell (Lossos et al, 2001; Ohshima et al, 2001, 
Uherova et al, 2001 and Barrans et al, 2002). The expression of CDIO and/or Bcl-6 in 
DLBCL is associated with better prognosis. Recent study using panels oFGC-B-cell and 
activation markers by immunohistochemistry on paraffin-embedded tissues developed 
these previous observations on DLBCL furtlier by suggesting three distinguishable 
expression patterns corresponding to GC-B-cell, AGC-B-cell and ANG-B-cell. These 
expression patterns appear to represent distinct clinicopathologic subtypes of DLBCLs 
thai have prognostic significances (Chang et al, 2004). 
5.6.1 Univariate Cox Proportional Hazards Regression Analysis 
Univariate Cox Proportional Hazards Regression Analysis was performed in both 
SNP positions of the IL-10 promoter and the biomarkers of all de novo DLBCL subtype, 
so that the impact of both SNP and biomarkers on the overall survival of DLBCL 
patients can be assessed. In our data, both SNP positions and DLBCL biomarkers had no 
impact on the overall survival of the DLBCL patients. These results were different from 
previous report that DLBCL subtypes, CDIO and MUM 1 have influences on the overall 
survival of comparable numbers of DLBCL patients (Chang et al, 2004). The different 
distribution of DLBCL subtypes in our locality and the low IL-10 production SNP 
haplotypes background in the Hong Kong population may account for these differences. 
Subtyping of the DLBCL and the IL-10 promoter SNP might not have similar clinical 
applications as in the Caucasion population. 
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5.6.2 Bivariate Cox Proportional Hazards Regression Analysis 
In order to investigate the effect of each DLBCL biomarkers in each prognosis 
parameters on the impact of the overall survival of DLBCL patients, Bivariate Cox 
Proportional Hazards Regression Analysis was performed. In our data, we could not see 
any significant impact on each prognosis parameters together with each DLBCL 
biomarkers. We could not detect any associations of CD 10 and Bcl-6 with prognosis of 
DLBCL patients. These contrast to the reports of better prognosis of DLBCL with the 
expressions of CDIO and Bcl-6 detected by others. Moreover, no significant impact was 
obtained with the prognosis analysis in all SNP positions of the IL-10 promoter. Hence, 
genotyping of IL-10 promoter and subtyping of DLBCL do not have any prognostic 
significance in the management of the local DLBCL patients. 
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Chapter 6: Conclusion 
The SNP genotypings of IL-10 promoter in positions -597, -824 and -1087 were 
performed in normal health control and NHL patients. Detailed analyses of SNP 
genotypings of the IL-10 promoter in different subtypes of DLBCL patients were also 
performed. 
Ill normal control, NHL and DLBCL patients, the most common alleles at positions 
-597, -824 and -1087 were A-allele, T-allele and A-allele, respectively. The most 
common genotypes at positions -597，-824 and -1087 in normal control and NHL 
patients were homozygous AA, homozygous 丁丁 and homozygous AA, respectively. The 
most common haplotype in all categories were ATA. The SNP genotypes of Hong Kong 
population were related to low IL-10 production. It is, therefore, likely that both NHL, 
including DLBCL, were developed in low IL-IO production backgrounds. 
The genotype of SNP of the IL-10 promoter in the control population at position 
-597 is linked with -824. The A-allele at -597 was followed by T-allele at -824; and 
C-allele at -597 was followed by C-allele at -824. In DLBCL patients, the most common 
genotype at -824 was heterozygous TC instead of homozygous TT as in normal controls. 
In some DLBCL patients, this linkage between positions -597 and -824 was disrupted. 
Rare haplotypes, ACA ATC and GCA, were discovered in DLBCL. These rare 
liaplotypes were not observed in normal control and NHL patients. These rare 
haplotypes might be associated with the susceptibility of DLBCL in the local population. 
The most common subtype of DLBCL in our series was ANGC-DLBCL, in 
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contrast lo the most common subtype of GC-DLBCL in the Caucasian population.. The 
overall distribution of DLBCL subtypes in our locality was also different from those in 
the Caucasian population. These indicated that the spectrum of DLBCL subtypes may be 
different among different ethnical groups. 
Prognostic analyses of the genotypes of each SNP positions and DLBCL 
biomarkers were performed. There were no significant impacts on the overall survival 
with each of the parameters analyzed individually and in combinations. These indicated 
thai the SNP genotypes of the IL-IO promoter and the DLBCL subtyping have little, if 
any, prognostic value in the local DLBCL patients. 
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